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 1 Introduction 
1.1 The heart - an overview 
1.1.1 Physiological function of the heart 
The function of the heart is to generate and maintain arterial blood pressure necessary to 
provide adequate perfusion of organs. The contraction of the cardiac walls elevates the blood 
pressure from the low filling values to the high pressures, at which the blood is ejected 
through the aortic valve into the aorta (Klabunde, 2011). Cardiac muscle has to contract 
repetitively for lifetime, and for that purpose it requires a continuous supply of energy. 
Cardiac muscle is therefore very rich in mitochondria, which regenerate ATP by oxidative 
phosphorylation of substrates and thus fulfill the myocardial energy requirements. To provide 
adequate O2 and substrates for the metabolic machinery, the myocardium is also endowed 
with a rich capillary network, about one capillary per fiber. 
Figure 1.1 Structure of the heart, and course of blood flow through the heart chambers and heart 
valves. (Guyton & Hall, 2006) 
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The heart consists actually of two separate pumps, the left heart and the right heart which 
have different functions. Each side of the heart is divided into two chambers, an atrium and a 
ventricle, connected by one-way valves, called atrioventricular (AV) valves, designed so that 
blood can flow only from the atrium into the ventricle. The left heart and the systemic 
arteries, capillaries, and veins form the systemic circulation. The left ventricle pumps 
oxygenated blood (in Fig. 1.1 red) to all organs of the body except the lungs. The right heart 
and the pulmonary arteries, capillaries, and veins build up the pulmonary circulation into 
which the right ventricle pumps deoxygenated blood (in Fig. 1.1 blue). The blood is pumped 
sequentially from the left heart into the systemic circulation, flows back to the right heart, 
which pumps it into the pulmonary circulation, and then back into the left heart (Guyton & 
Hall, 2006). 
The function of the heart is based on the highly coordinated contraction of cardiac muscle 
cells (cardiomyocytes). Their contraction is elicited by a depolarization of their membrane 
potential called action potential (AP). The AP is initiated in the sinoatrial node (SA node), 
which is located near the conjunction of the Vena cava with the right atrium. As the 
cardiomyocytes are connected by complexes of tight electrical and mechanical junctions, 
called intercalated discs, the AP is able to propagate rapidly over the heart and thus to elicit 
synchronized contraction of the cardiomyocytes, which is the pre-condition for the 
coordinated pumping of the heart. Likewise, refilling of the heart requires synchronized 
relaxation of the cardiomyocytes (Berne & Levy, 2008). 
The volume of blood pumped per minute by each ventricle of the heart is known as cardiac 
output (CO), which is defined as the product of heart rate (HR) and stroke volume (SV). In 
addition, further factors such as synchronization of ventricular contraction, ventricular wall 
integrity, and valvular competence affect CO (Fig. 1.2). SV is influenced by three main 
factors: (1) preload, which is the end diastolic pressure that stretches the right or left ventricle 
of the heart to its greatest geometric dimensions depending on the physiologic demand (the 
amount of myocardial fiber stretch at the end of diastole or the initial stretching of the 
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cardiomyocytes prior to contraction); (2) afterload, which consists of the resistance that the 
ventricle has to override to eject blood; and (3) contractility, which is a measure for the 
contractile performance of the heart independent of pre- or afterload (Kemp and Conte, 2012). 
As the preload depends on the filling of the respective ventricle this will also exert the 
stretching stimulus on the cardiac wall and thus the cardiomyocytes. The German physiologist 
Otto Frank was the first who observed a relationship between the volume present in the frog 
ventricle before the systole and the pressure developed during the systole (Frank, 1895). 
Expanding Frank’s perceptions, the British physiologist Ernest Starling showed, in an isolated 
dog heart, that the volume the ventricle ejected during systole was determined by the end-
diastolic volume (EDV). The principle underlying this relationship is the length-tension  
 
relationship in cardiac muscle fibers. The Frank-Starling law or relationship of the heart 
expresses that the volume of blood ejected by the ventricle depends on the EDV. The EDV 
itself is set by the volume returned to the heart, the venous return (VR). Hence, SV and CO 
correlate directly with EDV and VR. The Frank-Starling law ensures that the volume the heart 
ejects in systole equals VR. Therefore, in steady state CO equals VR (Patterson and Starling, 
1914). Increased diastolic filling produces a higher amount of stretch in the heart muscle, 
Figure 1.2 Mechanical and humoral factors affecting cardiac output.  
Stroke 
Volume 
Afterload Preload 
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Heart Rate 
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resulting in a larger SV. Furthermore, as the output of one ventricle becomes the VR of the 
other both must have the same volume.  
As mentioned above the third parameter scaling CO is afterload. Afterload is increased when 
systemic vascular resistance is up-regulated or an aortic valve stenosis occurs. Under the 
influence of elevated afterload, SV is lowered and end-systolic volume (ESV) rises. This 
results in a greater EDV, which in turn increases SV due to Starling´s law, and finally ends in 
a new steady state with higher systolic BP (Klabunde, 2007). 
Besides the mechanical regulation, cardiac output is also affected by the activity of the 
autonomous nervous system. The parasympathetic and the sympathetic component act 
antagonistically on the SA node. Parasympathetic stimulation leads to a lowering of the HR 
called negative chronotropic effect. Sympathetic stimulation exerts a positive chronotropic 
effect by rising the HR. As the CO depends directly on the heart rate, both branches of the 
autonomous nervous system also influence the CO in opposite directions (Fig. 1.2).  
Sympathetic stimulation furthermore increases contractile force (positive inotropic), 
accelerates relaxation (positive lusitropic), and speeds up excitation conduction (positive 
dromotropic).  
1.1.2 Cellular morphology of the cardiac muscle tissue 
The cardiac muscle tissue consists of muscle cells, named cardiomyocytes, fibroblasts and 
blood vessels. Cardiomyocytes are about ten times as long as wide, branched, and inter-
connected end to end by so called intercalated disks (ICDs), which appear as dark lines in 
light microscopy (Fig. 1.3 A and B).  
The intercalated disks contain firstly, gap junctions which connect the myocytes electrically 
and chemically, secondly, adherens junctions (AJs or fasciae adhaerentes) connecting the 
myofibrils from neighboring cardiomyocytes transferring the contractile force and finally, 
desmosomes (maculae adhaerentes) to provide mechanical strength to the ICDs (Forbes and 
Sperelakis 1985; Fig. 1.3 and 1.4). Later on, it has been reported that the development of the 
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mammalian ICD junctional system is continued also after birth. Interestingly, the AJs and 
desmosomes are fused and combined together which is called area composita (AC) 
(Borrmann et al., 2006: Franke et al., 2006; Pieperhoff and Franke, 2008). Moreover, the 
review article by Pieperhoff et al (2010) emphasized that the AC get involved in human 
arrhythmogenic cardiomyopathies (Pieperhoff et al., 2010).  
 
There are three different types of cardiomyocytes: (i) atrial, (ii) ventricular, as well as (iii) 
pacemaker and conductive cells. All three types of cardiomyocytes are cross-striated muscle 
cells filled with well-aligned contractile myofibrils already visible at the light microscope 
level. Cardiomyocytes usually contain one or two nuclei. 
 
A 
B 
Figure 1.3 The structure of cardiac myocytes.   
                    (Composed of Boron, 2009 (A); Nivala, 2012 (B)) 
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Each cardiomyocyte is surrounded by the cell membrane which in case of ventricular cells 
forms transverse tubular invaginations, T-tubules. The T-tubules pervade the cytoplasm from 
the cell surface to its center and they are flanked by an internal membraneous tubular 
network, the sarcoplasmic reticulum (SR), which plays a key role as internal Ca2+ stores. To 
provide the high amount of energy required for both contractions and the pumping of ions, 
cardiomyocytes contain a high amount of mitochondria situated in rows between the 
myofibrils (Fig. 1.3B) 
 
Figure 1.4 Diagrammatic representation of three structural zones of the intercalated disc. 
Note that the fascia adherens mainly anchors myofibrillar proteins, whilst the desmosome is 
mainly linked to the cytoskeleton (intermediate filaments and microfilaments). Five connexon 
channels are shown in the gap junction where each connexon is composed of six subunits, 
usually comprising connexin 40 and 43. (modified from Jung-Ching Lin et al. (2005) and Molt 
et al. (2014)).  
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Figure 1.5 Anatomy of the sarcomere.  
In the upper sketch a schematic drawing of one sarcomere is demonstrated. Thin filaments mainly 
consist of F-actin, tropomyosin, and the troponin complex (troponin T, C, and T). They are affixed 
at the α-actinin of the Z-discs. Thick filaments are based on myosin molecules, whose heads bind to 
the actin. Due to their ATPase activity the myosin heads are able to change their angle to the 
neighboring thin filaments and thereby to generate movement and force. Titin is a giant protein 
which expands from the Z-disc to the M-band. Titin is connected end-to-end in the Z-disc via titin-
cap (T-cap) and to α-actinin via so-called Z-repeats. In the middle sketch the bands of the sarcomere 
are represented. In the A-band (defined by the presence of myosin (A)) titin is attached to the thick 
filament. In the I-band (region, where the thin filaments are alone (I)) titin has its extensible region, 
which contributes to the elastic properties of the sarcomere. In the center of the sarcomere the 
myosin filaments are connected by the proteins of the M-band (M) e.g. myomesin and M-protein. 
The region in which the thick filaments do not overlap with thin filaments is called the H-zone (H). 
In an isolated living cardiomyocyte the length of a relaxed sarcomere is 1.8-1.9 µm. Thick filaments 
also contain further regulatory proteins like myosin-binding protein C (MyBP-C). Lower part 
consists of an electron microscopic picture of a longitudinal section of a sarcomere. Corresponding 
bands are located above each other. Figure by courtesy of Prof. Dieter Fürst, Inst. of Cell Biology, 
Bonn.  
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The myofibrils are divided into distinct, repetitive microanatomical units, termed sarcomeres, 
which form the elementary contractile units of the myocyte (Fig. 1.3 B). Each sarcomere is 
bordered by Z-discs (also called Z-lines), thus the distance between two Z-discs defines the 
sarcomere length. The sarcomere is mainly composed of the thick myosin- and thin actin-
containing filaments, as well as the sarcomeric cytoskeleton (Fig. 1.5). It is subdivided into 
bands, A-band (anisotropic), I-band (isotropic), which are named according to their refractory 
properties towards polarized light. 
1.1.3 The cytoskeleton of cardiomyocytes 
The cytoskeleton is an extensive network of filaments and accessory proteins that enables 
cardiomyocytes to withstand the extensive mechanical stresses that are developed during each 
contractile cycle of the heart.  
The backbone of the cytoskeleton is composed of three types of filaments: microtubules, 
intermediate filaments, and microfilaments. These filaments are linked to the myofibrils and 
to the cell membrane as well as to membranes of cellular organelles via a plethora of 
associated proteins. In addition, certain transmembrane proteins also connect the cytoskeleton 
to the extracellular matrix (ECM). In addition, myofibrils contain a specialized cytoskeleton 
based on the giant protein titin, which spans half sarcomere length and thereby links thick and 
thin filaments via several titin-binding proteins (Fig. 1.5). Thus the cytoskeleton supports the 
delicate cell membranes, positions organelles, supports intracellular transport, organizes 
myofilaments, and provides mechanical strength and structural integrity to the cardiomyocyte. 
The cytoskeleton of the myocytes is a vital structural network which also forms an interface 
between the cell and the extracellular environment through specialized transmembrane 
proteins like integrins and dystroglycans. Especially dystrophin binds to both, intracellular 
actin and extracellular laminin. Thus, the cytoskeleton enables the cardiomyocytes to form the 
cardiac tissue and to contract and relax in a coordinated manner. The cytoskeleton 
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additionally senses biomechanical stress and responds to it by induction of signaling 
pathways that allow the cell to adapt to these stimuli (Granzier, 2006).  
Elements of the cytoskeleton are involved in organizing structures such as costameres in 
striated muscle cells and in particular ICDs in cardiac muscle (Green et al., 2005). At an ICD, 
the cell membranes of 2 adjacent cardiomyocytes are extensively intertwined and bound 
together by gap junctions, adherens junctions and desmosomes (Fig. 1.4, 1.6). With respect to 
the cytoskeleton it is important to note that adherens junctions directly link the myofibrils 
mechanically, whereas the desmin intermediate filaments surround the myofibrils and 
connects them to the desmosomes. These connections help to stabilize the positions of the 
cells relative to each other and also help to maintain the 3D structural integrity of the tissue. 
Thus ICDs, as cardiac-specific structures, are responsible for both mechanical and electrical 
synchronization and are implicated in signal transduction between adjacent cardiomyocytes. 
It is worth to mention that the ionic channels like L-type Ca2+ channels, which play a key role 
in cardiac excitation-contraction coupling (c.f. chapter 1.5), are also linked to the 
cytoskeleton. Accordingly, it has been shown that pharmacological depolymerization of 
microfilaments by cytochalasin D reduced the Ca2+ inward current through L-type calcium 
channels (ICa,L) dramatically (Rueckschloss and Isenberg, 2001). In agreement with this 
observation, our group recently found that adult cardiomycytes deficient for gelsolin display a 
highly increased ICa,L and consequently also elevated shortening amplitudes (Weisser-Thomas 
et al., 2015). Gelsolin deficiency shifts the equilibrium of actin polymerization vs. 
depolymerization to higher degrees of polymerization, leading to more microfilaments in the 
cytoskeleton. The finding of an up-regulated ICa,L may also explain the observation that 
gelsolin-deficient mice are more prone to atrial fibrillation (Schrickel et al., 2009).  
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 In general, mutations or deficiencies in elements of the cytoskeleton have been found to be 
involved in various cardiac diseases. Especially, mutated ICD components cause 
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cardiomyopathies, arrhythmias and other fatal heart diseases (Li and Radice, 2010; Noorman 
et al., 2009; Perriard et al., 2003; Severs et al., 2008; Sheikh et al., 2009). 
Alterations in the amount and distribution of cytoskeleton elements also occur in 
cardiomyocytes of hypertrophied and failing myocardium. Furthermore, it has been shown 
that disruption of genes coding for cytoskeletal proteins such as the muscle LIM protein 
(MLP), desmin, plakoglobin, and N-cadherin can result in cardiac dilatation and impaired 
cardiac function (Jane-Lise et al., 2000). In addition, degeneration of cardiomyocytes can be 
induced by reduction of myofilaments as well as alterations of the cytoskeleton (Hein et al., 
2000). Also the heart’s participation in several muscular dystrophies has been deduced to 
mutations and variations in cytoskeletal proteins (Sarantitis et al., 2012; Clemen et al., 2013). 
Recently, a point mutation in desmin has been demonstrated to cause a myopathy and 
cardiomyopathy (Clemen et al., 2015).  
1.1.4 Xin repeat-containing proteins as part of the cardiac cytoskeleton 
As the function of the Xin repeat-containing proteins (XIRPs) in the heart will be in the center 
of this study, their role in the cytoskeleton of the heart is highlighted in a specific chapter. 
XIRPs are characterized by a 16 amino acid long conserved molecular motif (Xin repeat) 
which binds to actin filaments (Cherepanova et al., 2006; Choi et al., 2007; Pacholsky et al., 
2004). In mammals XIRPs are encoded by two genes, which originally were thought to be in 
linked to cardiac diseases and thus named "cardiomyopathy-associated (CMYA) genes" 
CMYA1 and CMYA3 (Walker, 2001). Recently, the genes have been renamed to XIRP1 and 
XIRP2, respectively. 
As the gene and protein-naming is inconsistent in different publications, the terminology used 
in this study is clarified in Table 1.1. 
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The intercalated disk protein Xin was originally discovered in chicken striated muscle and 
implicated in cardiac morphogenesis (Wang et al., 1999). In contrast to the chicken genome 
which seems to contain only one XIRP gene (Grosskurth et al., 2008), in mammals the 
mentioned two genes XIRP1 and XIRP2 are known (Pacholsky et al., 2004). In zebrafish even 
three XIRP genes have been identified (Otten et al., 2012). In mammals, the XIRP1 gene 
encoding XIRP1 consists of two exons, only one of which accounts for the protein-coding 
region. The situation is even more complicated, because intraexonic splicing of the XIRP1 
mRNA results in the expression of three Xin isoforms: XinA, XinB and XinC (van der Ven et 
al., 2006). It is quite likely that multiple splice variants exist also of XIRP2, but 
corresponding analyses still have not yielded a coherent image. 
In order to investigate the function of XIRP1, two types of XIRP1 deficient mice were made. 
Mice with a total XIRP1 deficiency (XinABC-/- mice) were bred by our group (Otten et al., 
2010), whereas mice lacking only two of the three XIRP1 isoforms (XinAB-/- mice) were 
introduced by Gustafson-Wagner et al. (2007). Based on the available literature and the 
splicing pathway, these XinAB-/- mice most likely are still able to synthesize the XinC 
protein. 
 
Protein family Gene name Alternative gene name Species 
XIRP1 
XIRP1 
 
Xin 
XIRP1 
XIRP1 
 
Xirp1 
hXina, , CMYA1, XIN 
mXinα, CMYA1, Cmya,  
mXin 
cXin 
human  
mouse 
 
chicken 
XIRP2 
XIRP2 
XIRP2 
XIRP2 
hXinβ, CMYA3, Cmya3  
mXinβ, CMYA3, Cmya3, 
Myomaxin  
human  
mouse 
 
 
(Gustafson-Wagner et al., 2007; Huang et al., 2006; Lin et al., 2005; Pacholsky et al., 
2004; Sinn et al., 2002; Wang et al., 1999; Wang et al., 2010, 2012; van der Ven et 
al., 2006),  http://www.ncbi.nlm.nih.gov/gene/241431; 
http://www.ncbi.nlm.nih.gov/gene/22437 
Table 1. 1   The Nomenclature of XIRPs 
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In differentiated skeletal muscle XIRPs are mainly found at myotendinous junctions, whereas 
in the heart they are localized in the ICDs (Wang et al., 2012). Furthermore, inactivation of 
Xin in developing chick embryos was reported to result in a severe disruption of cardiac 
looping morphogenesis (Wang et al., 1999). This suggests that the Xin gene may have played 
a key role in the evolution of the vertebrate heart (Wang et al., 2013). 
 
In the murine heart, XIRP1 has also been demonstrated in ICDs. As shown in Fig. 1.7, XIRP1 
is part of the fascia adherens of the ICD. Here β-catenin is bound to the cytoplasmic domain 
of N-cadherin. Furthermore, β-catenin is connected to α-catenin, which was suggested to 
either function as a linker between cadherins and thin filaments (Watabe-Uchida, et al., 
1998,), or alternatively to compete for the Arp2/3 complex to form an initiation complex for 
the assembly of actin filaments (Drees, et al., 2005). Free XIRP1 may first be in an auto-
inhibited state, during which the C-terminal proline-rich region prevents the Xin repeats from 
binding to actin filaments. As soon as XIRP1 binds to β-catenin with the respective binding 
domain, a conformational change could be induced. This may lead to an open conformation 
of the Xin repeats which are then able to bind with this region to actin filaments (Jung-Ching 
et al., 2005).  Interestingly, XIRP1 has also been detected in the regions of sarcomere repair 
Figure 1.7 Proposed model for XIRP1 (XinB) localization at the adherens junction of the 
intercalated disk (based on the ideas of Jung-Ching Lin et al. (2005) and Molt et al. (2014). 
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in cross-striated muscle together with filamin C and aciculin (Molt et al., 2014). This can be 
interpreted in the way that XIRP1 is involved in repair and remodeling processes in cross-
striated muscle. 
In 2004 a second protein with Xin-repeats was described as XIRP2 (Pacholsky et al., 2004). It 
binds to filamentous actin and α-actinin through the Xin repeat region in a fashion similar to 
XIRP1. In the heart XIRP2 was localized in ICDs (Gustafson-Wagner et al., 2007). At about 
the same time, Huang et al. (2006) described a new gene with Xin-repeats, which they called 
myomaxin. This gene was described as the murine ortholog of a partial cDNA named 
"cardiomyopathy associated gene 3" (CMYA3). This gene was shown to be controlled by the 
transcription factor "myocyte enhancer factor 2" (MEF2). The expressed protein was 
described to be related to Xin and was detected in the peripheral Z-disc region and costameres 
(Huang et al., 2006). In a later publication this group described the CMYA3 gene as XIRP2 
and consequently the expressed protein was called XIRP2 (McCalmon et al., 2010). The 
transcription factor MEF2 is stimulated by angiotensin II (AngII) a well-known pro-
hypertrophic factor. Indeed McCalmon et al. (2010) were able to show that AngII was able to 
up-regulate XIRP2 expression in cultured rat neonatal cardiomyocytes. Promoter assays in 
COS cells expressing the putative XIRP2 promoter and the type I angiotensin receptor 
provided evidence that the promoter region of the XIRP2 gene harbors an AngII responsive 
region. Like XIRP1 also XIRP2 seems to play a role in cardiac development, as loss of 
XIRP2 in mice led to ICD defects at postnatal day 16.5, a developmental stage when the heart 
forms ICDs (Wang et al., 2013). 
Surprisingly, the described XIRP1-deficient mice (XinAB-/- and XinABC-/-) exhibit different 
cardiac phenotypes. The XinAB-/- mice, which still can express XinC, are viable, fertile and 
display normal cardiac morphogenesis with cardiac hypertrophy, fibrosis conduction defects 
and signs of cardiomyopathy at higher age (Gustafson-Wagner et al., 2007). A significant up-
regulation of XIRP2 likely provides partial compensation and may account for the viability of 
the XinAB-/- mice (Gustafson-Wagner et al., 2007). Interestingly, XinC has been detected 
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solely in cardiomyopathic human tissues (Otten et al., 2010). As depicted in Fig. 1.7, mouse 
XIRP1 is potentially coupling the N-cadherin/β-catenin complexes to the underlying actin 
cytoskeleton, therefore XIRP1 deficiency may modulate ICD integrity and function. This may 
lead to the consequence that XinAB-/- hearts develop structural ICD defects and 
cardiomyopathy with conduction deficits (Wang et al., 2013). 
XinABC-/- deficiency, in contrast, leads to topographical ICD alterations, premature fibrosis 
and subtle changes in contractile behavior, which is a milder cardiac phenotype than that 
observed in XinAB-/- mice. Furthermore, it indicates that XinC may be dominantly involved 
in the development of human cardiac hypertrophy (Otten et al., 2010).  
Furthermore, McCalmon et al. (2010) generated a XIRP2 hypomorphic mouse, which spon-
taneously developed a mild type of cardiac hypertrophy. As discussed further down in chapter 
2.2, AngII is able to induce and promote the development of cardiac hypertrophy. 
Interestingly, AngII induced cardiac hypertrophy was attenuated in the XIRP2 hypomorphic 
mice.  
Taken together, these data predict a crucial role for XIRP1 and XIRP2 in cardiac development 
and disease and it will be of interest to determine the consequences of a disruption of both 
XIRP genes.  
1.1.5 The excitation-contraction coupling of cardiomyocytes  
Contraction of cardiac muscle cells is not initiated by neurons as in skeletal muscle but by 
electrical excitation generated by the cardiac pacemaker. This pacemaker consists of 
specialized cells located in the SA node of the right atrium. The pacemaker cells are able to 
undergo spontaneous depolarization and generate spontaneous and periodic APs. These APs 
are then propagated throughout the heart. By the following mechanism: when an AP is 
initiated in one cell, current flows through the gap junctions and depolarizes neighboring 
cells. If this depolarization reaches the threshold, then a new AP is elicited in this cell. This 
AP is again able to depolarize neighboring cardiomyocytes. By this mechanism APs 
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generated in the SA node can propagate over the whole cardiac muscle. Propagation of APs 
follows the specialized conduction system of the heart as these cells allow the highest AP-
conduction velocity (Boron, 2009).  
Function of the AP is to initiate the contraction of cardiomyocytes, this process is called 
electro-mechanical coupling (EC coupling). This function depends highly on the shape of the 
AP and on the underlying ionic currents. The cardiac AP introduced here, is typical for 
cardiomyocytes of the left ventricular myocardium of humans and other mammals with low 
heart rates (HR), i.e. resting rates of 60-80 beats per seconds.  The AP is divided into four 
phases: (0) the depolarization, (1) the partial repolarization, (2) the plateau phase, (3) the 
repolarization, (4) the resting potential (Fig. 1.8) Phase 0 is depending on a Na+ inward 
current through voltage activated Na+ channels. Phase 1 is evoked by a transient K+-outward 
current. The sustained depolarization during the plateau phase (phase 2) is maintained by a 
Ca2+-inward current through L-type Ca2+-channels and a reduced K+-conductance. The 
Figure 1.8 Action potential of a ventricular cardiomyocyte. (0) Depolarization due to Na+-
inward current, INa, through fast voltage activated Na+-channels. (1) Initial repolarization by a 
transient K+-outward current, Ito. (2) Plateau maintained by a Ca2+-inward current through L-type 
channels, ICa.L, and a reduced K+-conductance. (3) Repolarization depending on the K+-outward 
currents IKs and IKr. (4) Resting membrane potential stabilized by K+-current through inward 
channels, IK1.  
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repolarization during phase 3 is obtained by K+-outward currents through rapidly and slowly 
activating K+-channels. The main current component for the stabilization of the resting 
potential is K+-outward current through inward rectifier K+-channels. The duration of the AP 
lasts 200-300 ms. Rodents, which often exhibit higher HRs from 250-350 bpm (rats) or 550-
650 (mice), naturally have shorter AP-durations without a distinctive plateau phase.  
As the AP depolarizes the sarcolemma of the cardiomyocytes it also depolarizes the attached 
t-tubules. Here the depolarization opens voltage-gated L-type Ca2+ channels through which 
Ca2+ flows into the cytoplasm. This opens ryanodine receptor Ca2+ release channels (RyR) in 
the SR, which is located in direct vicinity of the T-tubular membrane. When the RyR 
channels open, stored Ca2+ is released from the SR into the cytosol, creating a Ca2+ “spark” 
that can be detected by Ca2+ sensitive fluorescent dyes like fura-2. Synchronized sparks from 
different RyR channels raise the cytosolic Ca2+-concentration, [Ca2+]i, sufficiently to elicit a 
uniform contraction of the cardiomyocyte. The [Ca2+]i is elevated approximately 10-fold from 
a resting level of ∼100 nM to ∼1 µM (Marks, 2003). As the myocardial RyR channels open 
in response to Ca2+ binding the mechanism of EC coupling in the cardiomyocytes has been 
named Ca2+-induced Ca2+-release (CICR; Fabiato,1985). Interestingly, 90% of the [Ca2+]i rise 
eliciting the contraction is provided by the SR and only 10% are flowing though L-type Ca2+ 
channels.  
Figure 1.9 Excitation contraction coupling in cardiac muscle. The figure shows the cellular 
events leading to contraction and relaxation in a cardiac contractile cell. 
  1. AP enters the T-tubule. 
  2. L-type Ca2+ channels open, Ca2+ flow into the cytoplasm. 
  3. Ca2+ induces Ca2+ release from the SR via ryanodine receptor-channels. 
  4. Local Ca2+ release induces Ca2+ spark. 
  5. Synchronously appearing sparks create a Ca2+ signal. 
  6. [Ca2+]i increases and Ca2+ binds to troponin C. 
  7. Cross bridge cycling starts, contraction develops. 
  8. Ca2+ is pumped back into the SR, [Ca2+]i is lowered. 
  9. Ca2+ dissolves from troponin C, relaxation develops. 
10. Ca2+ is pumped out of the cell by the Na+/Ca2+ exchanger. 
11. Cytoplasmic Na+ is maintained by the Na+ pump in the sarcolemma. 
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The Ca2+ ions bind to troponin and initiate the cycle of cross-bridge formation and 
detachment. The resulting mechanism of sliding filament movement is identical to that in 
skeletal muscle. 
Like in skeletal muscle, Ca2+ is transported back into the SR with the help of a Ca2+-ATPase. 
However, in cardiac muscle the Ca2+ originating from the extracellular space has to be 
removed from the cell. Each Ca2+ ion transferred out of the cell is transported against its 
electrochemical gradient in exchange for 3 Na+ entering the cell down their electrochemical 
gradient. The transport is via the Na+- Ca2+ exchanger (NCX). Sodium that enters the cell 
during this transfer is removed by the Na+-K+-ATPase (Fig. 1.9) (Silverthorn, 2008). Due to 
the falling [Ca2+]i the Ca2+ ions will dissolve from the troponin C and the cross-bridge cycling 
will cease allowing relaxation of the cells. 
In case of recordings of the contractile activity of the whole heart by intraventricular pressure 
catheter the time dependent pressure variations are used as contractility index, i.e. the peak of 
the first temporal derivative of the increasing pressure, dP/dtmax, is a well accepted measure of 
cardiac contractility (Fig. 1.10). The tangents in Fig. 1.10 visualize the differences in dP/dtmax 
Figure 1.10 The ventricular pressure curves. The slope of the ascending limb is maximal during 
the isovolumic phase of systole Left ventricular pressure curves with tangents drawn to the steepest 
portions of the ascending limbs to indicate maximal dP/dt values. A, control; B, hyperdynamic heart 
induced by administration of norepinephrine; C, hypodynamic heart, as in cardiac failure. (Berne & 
Levy, 2009) 
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in a control (A), in hyperdynamic (B) and a hypodynamic (C) heart. The hyperdynamic heart 
displays a decreased EDP, a steep pressure rise, a high peak (systolic) pressure and a fast 
pressure fall. In the contrast, the hypodynamic heart has an elevated EDP, a low dP/dtmax as 
well as a delayed and reduced peak pressure (Berne & Levy, 2008). 
1.2 Cardiac remodeling and hypertrophy 
The heart has to adapt to long lasting changes in pre- or afterload or to damages, which occur 
after myocardial infarction (MI), by structural changes of the cardiac tissue. This adaptation 
process is called “remodeling” (Cohn, 2000). A specific form of remodeling is the 
development of cardiac hypertrophy, which has been mentioned above in the chapter about 
XIRP. As the investigation of Xin repeat proteins is in the focus of this study, the induction of 
cardiac remodeling may be an important help to unravel the role of XIRP in the cardiac tissue. 
Therefore the process of remodeling specifically the development cardiac hypertrophy will be 
explained in detail in the following chapters.  
1.2.1 Adaptive or maladaptive remodeling 
The term “remodeling” usually describes processes that lead to variations in size and shape of 
the left ventricle, but sometimes it also used for the description of comparable conversions in 
the other cardiac chambers. At the point when the left ventricle is damaged for example by 
MI, heart attack or by cardiomyopathy changes often occur in the size and shape of the 
ventricle. Often ventricle becomes enlarged, its general shape is transformed from an 
elliptical to more spherical pattern, and the integrity of the muscular wall changed either it 
becomes thicker or thinner. The ventricular remodeling especially the initial remodeling that 
for instance occurs immediately after a heart attack can help the ventricle to compensate for 
the damage that has occurred, and may help the heart to continue pumping sufficiently. But if 
this initial remodeling is reduced after the first conversion phase, or worse, if the remodeling 
process continues, the changes in the ventricle are not any longer beneficial. They will 
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hamper cardiac function and finally induce its deterioration and transition to heart failure 
(HF). Furthermore, arrhythmias and ischemic heart disease may develop which increase the 
risk of sudden death (Cohn et al., 2000). 
In this context it is of interest that the application of inotropic drugs which help the diseased 
heart to contract more powerful, do not help to cure HF. Even more, despite their benefits on 
cardiac contractility inotropic drugs have been shown to accelerate death. In contrast, 
Angiotensin converting enzyme (ACE) inhibitors and β-blockers do significantly improve not 
only the symptoms but also the survival of patients with HF. These therapies also limit 
remodeling, and where remodeling has already occurred they can correct the size and shape of 
the damaged left ventricle. This ability of reverse remodeling is now thought to be extremely 
important in the therapy of heart failure to reduce symptoms and prolong survival (Cohn et 
al., 2000). Taken together, remodeling may be classified as adaptive or maladaptive 
depending on the time course and the degree of conversions in the myocardial tissue (Cohn et 
al., 2000; Dorn et al., 2003; Opie et al., 2006).  
1.2.2 Development of cardiac hypertrophy  
The following chapters will concentrate on the development of left ventricular cardiac 
hypertrophy as other types of remodeling are not relevant for this study. Development of 
cardiac hypertrophy is an adaptation of the heart to elevated work-load and is thus a very 
frequent type of cardiac remodeling. Development of cardiac hypertrophy can be induced by 
physiological as well as by pathological demands to the heart. 
Cardiac hypertrophy can be provoked by exercise or pregnancy in healthy individuals and is 
then characterized as “physiological”. In “physiological” hypertrophy the cardiomyocytes 
grow in length and diameter. This leads to an enlargement of the wall diameter as well as the 
volume of the ventricle. 
Fibrosis is not induced, but the vascular and capillary networks are in enlarged in proportion 
to the higher demands (Fig. 1.11). Physiological hypertrophy is often found in athletes after 
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intensive aerobic training as common in bicycle racing or rowing. This hypertrophy stays in 
the adaptive state for long time and can be reduced in case of a lowered work-load (Olson, 
2004).  
In contrast, hypertrophy that depends on pressure or volume overload is named 
“pathological”. Hypertension and aortic stenosis represent two different types of chronic 
pressure overload, both of which lead to development of left ventricular hypertrophy (LVH) 
(Gerdts, 2008). Pathological cardiac hypertrophy is associated with ventricular remodeling 
through alterations in the extracellular matrix that eventually impact cardiac function and 
energy use, and cause increased rates of myocyte cell death by apoptotic and necrotic 
mechanisms. Pathological cardiac hypertrophy can produce concentric hypertrophy in which 
the ventricular wall and septum thicken with a net decrease in ventricular chamber  
 
dimensions (Fig. 1.11). This remodeling is associated with a greater increase in cardiac 
myocyte width than length. Concentric remodeling is associated with incomplete LV 
Figure 1.11 Classification of ventricular remodeling patterns 
Physiological hypertrophy is characterized by a growth of the chamber lumen and an adequate 
wall the thickness, neither fetal genes are re-expressed nor is fibrosis induced. Pressure overload is 
usually compensated by concentric hypertrophy, often accompanied by fibrosis. Volume overload 
typically results in eccentric hypertrophy which is associated with mild or no fibrosis. Except for 
physiological hypertrophy, all other types of hypertrophic remodeling can progress to failure and 
dilation with dysfunctional myocytes (Figure slightly modified after Kehat, 2010: p. 16) 
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relaxation and increased filling pressures, i.e. increased left ventricular end diastolic pressure 
(LVEDP). 
Development of “pathological” hypertrophy can also form the phenotype of eccentric and 
dilatory hypertrophy. This usually results from a volume overload. Eccentric hypertrophy is 
based on elongation of cardiomyocytes. The signaling pathways leading to pure growth in 
length or to growth in thickness of the cardiomyocytes are not entirely understood. In spite of 
the name “pathological” this type of hypertrophy also starts with an adaptive phase to 
compensate increased wall stress and maintain output. This first phase is also named 
compensated hypertrophy. Eccentric remodeling helps to adjust the large increase in EDV 
(volume-overload) and maintain left ventricular ejection fraction (LVEF). The cellular 
alterations decrease wall thickness and dilate the heart, and eventually impair systolic 
function and reduce LVEF. 
Both described pathological forms of hypertrophy can proceed to a decompensated state, 
characterized by a dilated left ventricle, with relatively thin walls and an enlarged volume.  
This leads to declining ventricular function and may finally end in HF (Kehat, 2010) (Fig. 
1.11). Especially hypertension, which depends on an increase in the total peripheral resistance 
(TPR) of the vascular system, causes the development of concentric hypertrophy. 
Catecholamines as well as the renin angiotensin aldosterone (RAAS) system are well known 
as potent vasoconstrictors. Thus these hormones are often indirectly involved in the 
development LVH. It has been reported that catecholamines as well as angiotensin 2 (Ang II) 
also exert direct trophic effects on the heart, i.e. they directly induce cardiac hypertrophy 
besides their influence via the increased blood pressure. 
For the investigation of the development of pressure induced cardiac hypertrophy the model 
of transverse aortic constriction (TAC) has been introduced by Rockman et al. (1991). It is the 
commonly used model of pressure-overload in animals performed by constriction the aortic 
lumen between the brachiocephalic arteries and the left carotid artery. Although TAC initially 
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leads to compensatory hypertrophy of the heart, over time the response to the chronic 
hemodynamic overload becomes maladaptive resulting in cardiac dilatation and HF. 
1.2.3 Contribution of cardiomyocytes to hypertrophy  
Cardiac hypertrophy is based on changes in the cardiomyocytes as well as in the fibroblasts 
and the extracellular matrix. As cardiomyocytes are not any longer able to proliferate and 
stem cells like the satellite cells in skeletal muscle have not been proven, growth of the 
individual cardiomyocytes is necessary for any cardiac hypertrophy. The signaling pathways 
leading to physiological or pathological cardiac hypertrophy have been reported to be 
different. The differences in signaling between development of physiological and pathological 
cardiac hypertrophy have been reviewed extensively in Bernardo et al. (2010) and will be 
introduced here only briefly. 
Development physiological cardiac hypertrophy seems to depend mainly on insulin-like 
growth factor 1 (IGF1), which is produced in the liver due to increased somatotropin levels in 
the blood. Cardiomyocytes carry IGF1-receptors on their surface which signals via 
phosphoinositide 3-kinase (PI3K), Akt (or Protein kinase B (PKB)) and mammalian target of 
rapamycin (mTOR). Interestingly, IGF1 is also expressed by the cardiomyocytes themselves. 
Under experimental conditions, IGF1 led to cardiac growth resembling physiological 
hypertrophy and aerobic exercise induced increased IGF1 levels in the heart. Cardiomyocytes 
grow in length but also in diameter by increasing the number of myofibrils per cell and by 
integrating additional sarcomers into the myofibrils. Fibrosis is not induced in this process.  
Onset of pathological pathological hypertrophy seems to be started by different processes. 
The increased workload of the heart in both, pressure or volume-overload, induces sustained 
wall stress. This may be transferred by different elements of the cytoskeleton to mechano-
sensitive ion channels (reviewed in Calaghan et al., 2004) as well as to protein kinases, which 
start specific signaling cascades (reviewed in Lyon et al., 2015). Mechanotransduction may 
start at intracellular structures like the Z-lines or at the ICDs, which transmit mechanical force 
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between neighboring cardiomyocytes, and also contact structures between the ECM and the 
cells like focal adhesion plaques or dystroglycan complexes.   
Very interesting hypotheses about mechanotransduction have been proposed by Lyon et al. 
(2015) and incorporated in Fig. 1.6. Four-and-a half LIM domain protein1 (FHL1) and 2 
(FHL2) is bound to titin near the Z-line (Review: Krüger and Linke, 2009). Titin is involved 
in the elasticity of the cardiomyocyte and thus is differentially stretched depending on the 
mechanical load of the cardiomyocyte. The stretch differences may enable FHL1 to activate 
extracellular-regulated kinase-2 (ERK-2), mitogen activated protein kinase kinase-2 (MEK2), 
and/or rapid accelerated fibrosarcoma-1 (RAF1). Interestingly, mice deficient of FHL1 have 
been shown to develop a blunted hypertrophic response to TAC (Review: Chu and Chen, 
2011). The role of FHL2 in the development of cardiac hypertrophy is still under discussion. 
Recently our group found that FHL2 deficiency protects against TAC dependent cardiac 
hypertrophy in an indirect way (Goltz et al., submitted).Comparable protein-complexes are 
also involved in transducing the pro-hypertrophic effects of Ang II, norepinephrine (NE) and 
endothelin1 (ET-1) (c.f. review Bernardo et al., 2010). These pathways induce re-expression 
of fetal genes leading the typical alterations in the proteins involved in excitation-contraction 
coupling.  
Another aspect of specific interest for this study is reviewed in Lyon et al. (2015). N-cadherin 
(N-CAD) is part of the fascia adherens and allows to transmit mechanical forces between 
adjacent myofibrils (Fig. 1.6, 1.7). These adherens structures have to be rebuilt due to 
increased wall stress under pressure or volume-overload. Here also XIRPs have been located. 
Chopra et al. (2011) found that N-CAD containing adherence structures were able to induce 
cardiomyocyte remodeling in response mechanical stress. 
Concentric remodeling of the heart is associated with duplication of sarcomeres in parallel 
and cardiomyocyte thickening, and is the direct result of sustained pressure increase. 
Eccentric remodeling of the heart is associated with duplication of sarcomeres in arrangement 
and lengthening of cardiomyocytes in order to increase the chamber volume. Furthermore, the 
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density of desmin filaments increases during remodeling to compensate pressure overload 
(Wang et al. 1999). In agreement with this finding desmin-deficient mice develop cardiac 
hypertrophy (Milner et al., 1999). The degree of desmin remodeling has even been 
demonstrated to be a very precise predictor for the transition from compensated to 
decompensated hypertrophy (Monreal et al. 2008). Pressure induced cardiac hypertrophy also 
induces the amount cytoskeletal microtubules (Tagawa et al., 1996). Also the stiffness of titin 
changes during development of cardiac hypertrophy due to an isoform switch (Hutchinson et 
al., 2015). This switch also varies the signaling characteristics of this molecule which have 
been discussed above. Also XIRP proteins have been shown to be involved in the 
development of cardiac hypertrophy as explained in chapter 1.4. Taken together, 
modifications of cytoskeletal proteins are both a cause and consequence of contractile 
dysfunction and cardiac remodeling (Sequeira et al., 2013). 
1.2.4  Mechanisms of fibrosis 
The organization of the ECM is very important for the arrangement cardiomyocytes within 
the ventricular wall and fibroblast proliferation and fibrosis play an important role during the 
formation of cardiac hypertrophy Therefore, the following section will introduce the 
mechanisms of fibrosis.  
Collagen type I and type III constitute the majority of the fibrillar collagen content of the 
myocardium. The collagen network within the LV is highly organized. Alterations in this 
network influence structure and function of the LV. In response to pressure overload the 
collagen expression is increased. This in turn elevates stiffness of the ventricular walls and 
makes the LV less compliant and leads to abnormalities in diastolic function. In contrast, a 
degradation of collagen results in an increasing compliance and dilatation of the LV 
(Deschamps and Spinale, 2006).  
In a healthy heart turnover of collagen is relatively low and deposition and degradation are in 
steady state. Under pathological conditions collagen turnover is up-regulated. Collagen 
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turnover depends on the balance of matrix metalloproteinases (MMPs) and the tissue 
inhibitors of metalloproteinases (TIMPs). 
Dysregulation of this balance can be brought about by a number of factors (Siwik and 
Colucci, 2004). In cardiac fibroblasts, the inflammatory cytokines such as interleukin-1β (IL-
1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) decrease collagen synthesis, 
increase MMP expression and decrease TIMP expression (Li et al., 1999; Siwik et al., 2000). 
Inflammatory cytokines are tightly linked to tissue stress and their production is induced 
following biological stimuli such as pressure overload and myocardial injury. Transforming 
growth factor-β (TGF-β) is an anti-inflammatory cytokine and a potent stimulator of collagen 
synthesis. It mediates collagen accumulation through increasing transcription, stabilizing 
procollagen mRNA, and decreasing collagen degradation via enhanced TIMP or reduced 
MMP expression. Sustained production of TGF-β underlies the development of myocardial 
fibrosis (Kassiri and Khokha, 2005). TGF-β is secreted in an inactive form and proteolytically 
activated by proteases like MMPs. Its activation is supported by tissue damage and cellular 
stress (Annes et al., 2003). TGF-β induces secretion of several ECM components by 
fibroblasts (Desmouliere et al., 1993). The ECM has a major influence on cell migration, 
proliferation, adhesion, and cell-to-cell signaling (Geiger et al., 2001; Weber et al., 1994). 
TGF-β antagonism lowers fibrosis and thereby also the symptoms of HF (Lars et al., 2013). 
The development of LV dilation has been shown to be associated with discontinuity and 
disruption of the supporting fibrillar collagen network, abnormalities in the degree of collagen 
crosslinking and defects in basement membrane structure and function (Baicu et al., 2003; 
Candido et al., 2003; Factor, 1994; Spinale et al., 1991; Spinale et al., 1996; Weber et al., 
1992).  
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1.3. Aim of the study 
In chapter 1.1.3 the importance and the functions of the cytoskeleton of cardiomyocytes have 
been described. Furthermore, mutations in different proteins of the cytoskeleton have been 
shown to cause or to be associated with the pathogenesis of cardiomyopathies and the cardiac 
symptoms in several muscular dystrophies. In addition, cardiac arrhythmias have been 
attributed to such mutations (Fatkin et al., 2010; Ho, 2010; Marian, 2010; Modica-Napolitano 
and Singh, 2002; Nerbonne and Kass, 2005).  
Previously, our group found that ablation of all XIRP1 isoforms (XinABC-/- mice) under 
normal conditions resulted in a milder phenotype than that observed in XinAB-/- mice, which 
still can express XinC (Otten et al., 2010). Based on this study, we hypothesized that 
complete XIRP1 deficiency may have more drastic consequences, if development of 
pathological hypertrophy is induced by TAC. During this remodeling process changes in the 
ICD become evident. As XIRP1 is an element of the fascia adherens (c.f. Fig. 1.7), its 
deficiency may leads to alterations during the remodeling of the ICDs. However, we found 
that the extent of cardiac hypertrophy did not differ between wild type and XinABC-/- TAC 
mice (Kebir et al., in preparation). A possible explanation could be that XIRP2 may be up-
regulated in XIRP1 deficiency and thus substitute for XIRP1 in these cardiomyocytes. Thus 
we hypothesized that an additional knock-down of XIRP2 may help to unravel the functions 
of both XIRPs in the murine heart. To investigate this, XinABC-/- mice (Otten et al. 2010) 
were crossed with XIRP2 hypomorphic mice (McCalmon et al., 2010) and the resulting 
animals referred to in the following as XIRP1XIRP2 dko. The cardiac phenotype of the 
XIRP1XIRP2 dko mice was investigated under physiological conditions and after induction 
of cardiac hypertrophy by TAC. 
 
 
 2 Material and Methods 
2.1 Experimental animals  
To generate the mouse model, XinABC-/- mice (Otten et al. 2010) were crossed with XIRP2 
hypomorphic mice (McCalmon et al., 2010) and the resulting animals referred to in the following 
as XIRP1XIRP2 dko). XIRP wild-type (XIRP WT) female, XIRP1XIRP2 dko female mice from 
the “Institut für Zellbiologie were used for this study. After delivery, the mice were housed 
individually ventilated in polycarbonate transparent pathogen-free cages (365x207x140 mm) with 
animal bedding (ASBE-wood GmbH, Ahrensfelde, Germany) at a room temperature of 20-22 °C, 
50% humidity and 12 hours day-night cycle. The mice were given free access to standard rodent 
chow (ssniff Spezialdiäten GmbH, Seost, Germany) and water ad libitum. All mice were handled 
according to the principles of laboratory animal care (NIH publication no: 85-23, revised 1996) 
and experimental procedures followed the rules of the German Protection of Animal Acts from 
18th of May, 2006; changed on 7th of August 2013 (Animal rights 18th May 2006, changed 7th 
August 2013) 
2.2 Experimental protocols  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 An overview of experimental protocols. 
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The 11-13 week-old adult mice were divided into 4 groups. 
 
1. XIRP WT sham 
2. XIRP WT TAC 
3. XIRP1XIRP2 dko sham 
4. XIRP1XIRP2 dko TAC 
Half of them underwent to the Transverse aortic constriction (TAC) operation whereas the sham 
groups were operated without aortic ligation. The purpose of TAC is to reduce the diameter of the 
aorta to one third (Fig. 2.2). TAC is a model of pressure overload induced cardiac hypertrophy 
and heart failure (Rockman et al., 1991). The mice were allowed to develop hypertrophy for 14 
days.  
 
 
(1) TAC surgery in mice causes chronic left ventricular (LV) pressure overload, progressive left 
ventricular hypertrophy (LVH), and subsequent cardiac failure, providing an experimental model 
for human cardiac response to systemic hypertension. Since its development, the TAC model has 
been used extensively on genetically engineered mice to investigate the role of specific genes 
Figure 2.2 Transverse aortic constriction. To induce pressure overload, the aortic is tied between 
the brachiocephalic trunk and the left common carotid artery (Slightly modified from Rockman et al., 
1991). 
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during the development of LVH and cardiac failure in vivo (Barrick et al., 2006). The murine 
TAC model (Rockman et al., 1991) was proven to be a valuable tool to mimic human 
cardiovascular diseases and elucidate fundamental signaling processes involved in the cardiac 
hypertrophic response and heart failure development. When compared to other experimental 
models of heart failure, such as complete occlusion of the left anterior descending (LAD) 
coronary artery, TAC provides a more reproducible model of cardiac hypertrophy and a more 
gradual time course in the development of heart failure (Angela et al., 2010). To standardize the 
degree of aortic constriction a 27-gauge needle was used as a placeholder to pass a suture 
underneath the aortic arch (Baumgarten et al., 2002). In this study mice were allowed to develop 
hypertrophy for 14 days after the initial surgery (Harada et al., 1998) (see chapter 2.3.1). 
(2) For the hemodynamic measurement (an invasive pressure measurement), the hemodynamic 
parameters heart rate (HR), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), left 
ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), were 
recorded using an Ultra-Miniature Pressure Catheter (Scisense advancing micro-sensor 
technologyTM, USA/CAN). All mice independent of TAC or sham operation were monitored 14 
days later. Following induction of anesthesia, the ultra-miniature pressure catheter was 
retrogradely inserted through the right common carotid artery into the LV. After stabilization, 
hemodynamic parameters were recorded while anesthesia was maintained at 1 vol % isoflurane 
(see chapter 2.3.2). Euthanasia was performed by deep anesthesia (4% isoflurane) then hearts and 
lungs were excised immediately. Both were weighted, the heart was prepared further by cutting 
off both atria and then dividing LV and RV which were weighted separately. Finally, all organs 
were snap frozen in liquid nitrogen and stored at −80◦C for molecular analysis. Some of the hearts 
after excision were fixed by 4% Paraformaldehyde (PFA) (4 g of PFA powder and 100 ml of PBS 
(0.137 M NaCl, 0.05 M NaH2PO4, pH 7.4)) for histological studies.  
(3) Besides the morphometric parameters, body weight (BW), heart weight (HW), left ventricular 
weight (LVW), right ventricular weight (RVW), lung weight (LW), which were weighted, tibia 
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length (TL) was measured by a caliper to calculate individual BW/TL, HW/TL, LVW/TL, 
RVW/TL, LW/TL ratios (see chapter 2.4.2).  
(4) For histology, hearts were excised after blood pressure and Electrocardiogram (ECG) 
recordings and perfused in a Langendorff apparatus with Ca2+-free Tyrode solution (in mM: 135 
NaCl, 4 KCl, 1 MgCl2, 2 HEPES, and 2.6 EGTA; pH 7.4) for 5 min then perfused with 4% PFA 
8-10 min, fixation and embedding were performed consecutively. Paraffin embedded hearts were 
cut into 5 µm sections and submitted to Masson trichrome staining. Interstitial fibrosis and LV 
diameter were quantified using Image J analysis software (Version 1.47; Wayne Rasband, 
National Institutes of Health, USA) (see chapter 2.4.1). 
(5) In immunohistochemistry staining of isolated cardiomyocytes, hearts were excised and 
isolated ventricular cardiomyocytes were prepared by perfusing excised hearts in a Langendorff 
apparatus. The isolated cardiomyocytes which were attached to laminin-coated microscope slides 
were then fixed with cold (–20°C) methanol (5 min) and acetone (0.5 min). Cell width and length 
of 56-100 cells of each animal were measured using an ocular micrometer. Cardiomyocytes were 
stained with antibodies to localize intercalated disk (ID) proteins using standard procedures. The 
localization of IDs was evaluated statistically. The following antibodies were used for primary 
antibody: anti-FLNC RR90 antibody (Van der ven et al., 2000), specific for Filamin A and C d1-
2, respectively; T12 antibody (Fürst et al., 1988) specific for Titin Z-band epitope; CX43 antibody 
(AG Willecke) specific for gap junction; CDH antibody (Sigma, Munich) specific for cadherin; 
myosin heavy chain 20 antibody (Mf20) (Developmental studies hybridoma bank, Iowa, USA) 
34C-s antibody (Developmental studies hybridoma bank, Iowa) specific for Rryanodine receptors; 
FlnC antibody (AG Fürst) specific for filaminC d16-20; BB78.8 antibody (Vinkemeier et al., 
1993) specific for Myomesin, M-Band. For secondary antibody, the following antibodies were 
used; Goat anti mouse IgG1 Alexa 594 (SouthernBiotech, Alabama, USA); Goat anti mouse IgA 
FITC (Invitrogen, Darmstadt); Goat anti rabbit-Alexa 647 (Jackson, Darmstadt); Goat anti mouse 
IgG1 Cy2 (Invitrogen); Goat anti mouse IgG2b-Alexa 594 (Molecular probes); Goat anti rabbit 
Alexa 647; Goat anti mouse IgG1 Cy2; Goat anti mouse IgG2A-Alexa 594; Goat anti rabbit-
32 
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Alexa 647. Dapi (Invitrogen) blue fluorescent nuclear stain was used to visualize nuclei. The 
cardiomyocyte slides were examined and pictures were acquired using an inverted microscope 
equipped with fluorescence optics (Nikon Eclipse TE-2000-E) and a cooled CCD camera (DVC 
company, Texas, USA) and Image Pro Plus software (Media Cybernetics, Surrey, Canada) (see 
chapter 2.4.3). Cell isolations and fixations were performed by the author. Antibody binding and 
immunofluorescence microscopy was performed by J. Schuld Institute of Cell Biology. 
 
2.3 In vivo experiments 
2.3.1 Transverse aortic constriction 
TAC was performed to induce increased afterload in the heart which leads to heart failure. The 
method was adopted by Rockman et al (1991) and slightly modified. TAC was performed in 11-
13 week-old adult female XIRP1XIRP2 WT, XIRP1XIRP2 dko mice. 
 
2.3.1.1 The operating field 
The operating field was disinfected with 70% ethanol. The operation stage (Fig. 2.3 a) was 
connected to the water bath (Fig. 2.3 b) to let the water circulate under the animal to maintain the 
temperature at 37 °C ± 1 °C. It is very important to maintain the normal body temperature during 
surgery to avoid a rapid decrease in heart rate. The surgical tools were sterilized by the autoclave 
before surgery. The surgical instruments used were: curved scissor, mosquito clamp, fine curve 
forceps x 2, cubic curve forceps x 2, chest retractor x 2, and needle holder (Fig. 2.4). 
 
 
 
 
 
 
 
 Material and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
d 
e 
g 
h 
b 
c 
f 
Figure 2.3 The setup for small animal surgeries. (a) The operation stage, (b) the stereo microscope 
with electrical focus and camera, (c) the mini ventilator, (d) the water bath, (e) the anesthesia 
induction chamber, (f) the infrared lamp, (g) the isoflurane vaporizer, (h) the oxygen flow meter. 
Figure 2.4 The surgical instruments. Include; fine curve forceps x 2, cubic curve forceps x 2, 
scissor, mosquito clamp, and needle holder (from left to right). 
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2.3.1.2 Endotracheal intubation 
The mouse was weighed on a digital scale (Kern EMB 500-1, Precision balance, KERN & 
SOHN, Balingen) then was anesthetized in a transparent induction chamber (Fig. 2.3 e) which 
was pre-filled with 2% isoflurane mixed with 0.5 - 1.0 l/min 100% O2 for anesthesia induction. 
When muscle relaxation was obvious, the mouse was removed from the transparent induction 
chamber placed in a supine position with paws and tail taped to the heated operation stage. 
Anesthesia was maintained by continuous inhalation of 2% isoflurane. The eyes of the mouse 
were painted by eye ointment (Bepanthen®, Bayer vital GmbH, Leverkusen, Germany) to prevent 
air irritation to the eyes. The mouse’s nose was put into the wide side of a pipette tip that was 
connected to the plastic tube, which was ended in a Y-branch. By the Y-branch the 2% isoflurane 
flow from the isoflurane vaporizer (Fig 2.3 g) was combined with a flow of 100% O2 (0.5% - 
1.0% l/min) from an O2 flow meter (Fig 2.3 h) to provide a continuous supply of 2% isoflurane. A 
temperature probe that was connected to a temperature controller was inserted into the mouse 
rectum to measure the body temperature. If the mouse body temperature was lower than 37 °C an 
infrared lamp was switched on until 37 °C was restored. A thread was placed around the animal’s 
front upper teeth to extend the neck. The tongue was carefully pulled out using a cubic curved 
forceps. A hair removing cream was used to remove the fur from the neckline to mid chest level 
(Fig. 2.5 a and b). A middle skin longitudinal incision was made on the neck and extended down 
to the xiphoid by using a curve scissor. The submandibular salivary glands and sternothyroid 
muscles were separated respectively, and then the trachea and larynx were exposed. The cubic 
curve forceps was held in the left hand to fix the larynx and the endotracheal tube was inserted 
advanced towards to the larynx, and then pushed into the trachea by the right hand at the same 
time. Finally the mouse was attached to a Harvard volume-cycled rodent ventilator (MiniVent 
845, Hugo Sachs Elektronik, March-Hugstetten, Germany) (Fig 2.3 c) cycling at 110 
breaths/minute and a tidal volume of 0.2 ml. During the surgical procedure, anesthesia was 
maintained at 2.5% isoflurane with 0.5 - 1.0 l/min 100% O2.for anesthesia. The mouse was 
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a b 
injected with buprenorphine (0.1 mg/kg) (Buprenorphine hydrochloride 0.3 mg in 1 ml, Reckitt 
Benckiser Pharmaceuticals Inc, Richmond) intraperitoneally.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
head 
Submandibular salivary glands 
Forceps Forceps 
Trachea with 
Endotracheal tube 
Submandibular salivary glands 
Trachea  
Figure 2.6 Endotracheal intubation. The inserted cannula can be confirmed with direct vision through the 
exposed trachea. (a) The arrows indicate the direction of inserted cannula, (b) exposed trachea before 
intubation and after intubation  
a b 
Figure 2.5 Hair removing. (a) Before use hair removing cream and (b).after used hair removing cream.  
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2.3.1.3 Ligation of the transverse aorta 
Under a surgical microscope, the skin was disinfected with povidone-iodine solution (Betaisodona 
Lösung®, Mundiphama GmbH, D-limburg) and opened consecutively. The left pectoralis major 
and minor muscle were bluntly dissociated until the rib was exposed (Fig. 2.8 a). A parasternal 
incision was made to open the chest by cutting the left second and third ribs with the curved 
scissor. The chest retractors were used to open the thorax and to stop bleeding at the same time 
(Fig. 2.8 b). Fine curved forceps were used to gently separate the thymus and fat tissue from the 
aortic arch. The aortic arch was visualized (Fig. 2.8 c). The 5–0 silk suture was passed underneath 
the aortic arch between the brachiocephalic trunk and left common carotid artery (Fig. 2.8 d). 
Two loose knots were tied around the transverse aorta and a small piece of a 27½ gauge blunt 
needle was placed parallel aortic arch between the aorta and a first knot (Fig. 2.8 e). The first knot 
was quickly tied against the needle, followed by a second one, then the needle was promptly 
removed (Fig. 2.8 f). In sham control mice, the entire procedure was identical except for the 
ligation of the aorta. The chest retractors were removed and the thorax was closed then the skin 
was sutured with a continuous suture pattern by using a 6.0 prolene suture (Nahtmaterial 6-0 
a b 
Figure 2.7 Mini-ventilator and the endotracheal tube connection (a and b) 
 Available from http://www.hugo-sachs.de [7 January 2015]. 
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Prolene®, Ethicon GmbH, D-Norderstedt) (Fig. 2.8 h). Finally, the wound was disinfected with 
povidone-iodine solution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
e f 
g h 
Figure 2.8 The transverse aortic constriction. (a) The left pectoralis major and minor muscle 
dissection, (b) the thorax cavity was opened by the retractors, (c) the aortic arch, (d) the thread was 
passed underneath the aortic arch between the brachiocephalic arteries and left common carotid 
arteries, (e) the small piece of a 27½ gauge blunt needle was placed parallel aortic arch between the 
aortic artery and the first knot, (f) the aortic ligation, (g) the thorax was closed, (h) the skin suture.  
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2.3.1.4 Post-operative recovery 
Anesthesia was gradually decreased from 2.5% to 1% and then turned off. The outflow of the 
ventilator was pinched off for 2 seconds to re-inflate the lungs. Then endotracheal tube was 
removed when signs of spontaneous breathing occurred. The mouse was moved to the prone 
position and allowed to recover under the infrared heating lamp. After the mouse had woken up, it 
was placed in a cage under infrared light and observed for 20 minute. Finally, the mouse was 
transferred back to the housing cage. 
 
 
2.3.2 Hemodynamic measurement 
Two weeks after TAC, the mouse was re-anesthetized with isoflurane as described in 2.3.2.3 to 
determine the degree of pressure overload induced by ligation of the transverse aorta. This 
evaluation was based on invasive blood pressure recording. 
 
 
2.3.2.1 The catheter preparation 
 
2.3.2.1.1 The equipments 
1. Ultra-miniature pressure catheter (Transonic System Inc, NW Maastricht, 
Netherlands) (Fig. 2.9 a) 
2. FP095B-Dual channel pressure control unit version 095B-01 (Transonic System Inc, 
NW Maastricht, Netherlands) (Fig. 2.9 b and c) 
3. Powerlab/8SP (ADInstruments Ltd, Spechbach, Germany) (Fig. 2.9 d) 
4. Computer (Hewlett-Packard GmbH, Böblingen, Germany) running LabChart v6.0 for 
Windows (ADInstruments Ltd, Spechbach, Germany) 
 
2.3.2.1.2 Calibration method 
An ultra-miniature pressure catheter was plugged into the FP095B-Dual channel pressure control 
unit that was connected to the Powerlab /8SP data acquisition system and the computer 
consecutively. The complete measuring system was turned on. The labChart program was run at a 
 Material and Methods 
 
sampling rater of 1 kHz. Then the purple 0 mmHg button was pressed in order to enable the 
LabChart program to digitize the voltage referring to 0 mmHg. In the next step the 100 mmHg 
button was pressed to transfer the voltage for this pressure into the LabChart program. In the 
LabChart program we have to choose set up 2 point calibration and unit conversion. Finally, both 
voltages are now combined with the referring pressures (Fig. 2.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d 
a b 
Figure 2.9 The calibration equipment. (a) The pressure catheter, (b) the dual pressure control box, (c 
and d) the front and back panel of the dual pressure control box. Scisense System Inc., (2010). 
Pressure measurement system use and care. Ontario, Canada. 
a b 
Figure 2.10 The PowerLab/8SP. The front and the back panel of the PowerLab/8SP (a and b) 
ADInstruments Pty Ltd, (2001). PowerLab SP owner’s guide. NSW, Australia. 
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2.3.2.2 Running the experiment 
The data acquisition system has to be calibrated as described in the previous section. The sensing 
tip of the pressure catheter was pre-soaked in a saline solution for at least 20 minutes to allow the 
sensor to hydrate properly before use and to minimize baseline pressure drift during the 
experiment. After removing the catheter from the saline solution, the pressure signal (s) had to be 
set to zero by using the Coarse and Fine button controls on the dual channel pressure control unit 
before catheter insertion. Then the cath on button on the pressure box was pressed on and the 
catheter was ready to be advanced into the blood vessel. 
 
 
2.3.2.3 Preparing the Mouse 
The mouse was anesthetized in the transparent induction chamber with 2% isoflurane mixed with 
0.5 - 1.0 l/min 100% O2. The mouse body temperature was maintained at 37°C by the described 
feedback loop between rectal probe and infrared lamp. The skin above the neck on the right side 
was cut and the cube forceps were used to separate left and right submandibular salivary glands. 
Then a blunt cotton bud was used to gently access the area right to the trachea to visualize the 
right common carotid artery. Three 6-0 prolene sutures were passed underneath the right common 
Figure 2.11 Screen shot of units conversion. 
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carotid artery by a fine forceps and arranged to be proximal middle and distal. The proximal 
suture was placed as proximal as possible and tied. The middle suture was done up in a loose knot 
and the distal suture was fixed by a small curve clamp (Fig. 2.12 a). A small incision was cut into 
the artery by the fine vannas scissors just above the proximal knot through which the pressure 
catheter was inserted (Fig. 2.12 b). The middle knot was fastened and the small curve clamp that 
fixed the distal suture was loosed then the pressure catheter was advanced. Before the recording 
started the isoflurane concentration was decreased to 1% keep the HR above 500 beat/min (bpm) 
(Fig. 2.12 c). After 5-10 minutes, when the blood pressure was stabilized, and the pressures 
catheter was advanced into the LV. To conform the correct position of the pressure catheter tip in 
the LV, the dramatically decreased DAP and the changed in the waveform of ventricular pressure 
recording were considered (Fig. 2.14 a). The LVP was recorded for approximately 10 minutes. 
Afterwards, the isoflurane concentration was increased to 4 % and the whole heart and lung were 
explanted and weighted, LV and RV were separated and then weighed. Finally, the tibia was 
performed and its length was measured.  
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a 
b 
c 
The common carotid artery 
The common carotid artery 
 after incision 
The pressure catheter 
Figure 2.12 Pressure catheter insertion. (a) Ventral view on to the neck region of a mouse; 
common carotid artery after preparation and fixation with silk threads, 10x magnification (Bittig, 
2005), (b) ventral view of the neck region of a mouse after insertion of the catheter in the carotid 
artery, 16-fold magnification (Vervölgyi, 2007), (c) ventral view of the neck region of a mouse after 
incision of the vessel, next to it is the pressure catheter, 10-fold magnification (Vervölgyi, 2007).  
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2.3.3 Hemodynamic data analysis  
 
The data of the hemodynamic measurements were analyzed offline using the Chart 6 for 
Windows ® program (ADInstruments). For analysis and display of display of cycle-by-cycle 
parameters from arterial or ventricular pressure recordings the Blood Pressure Module was 
applied for analysis of arterial and ventricular pressure recordings and to calculate a variety of 
parameters (Fig. 2.13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.3.1 Setting the module to analyze the data 
 
For offline analysis labChart was opened and a file was chosen. Then the blood pressure setting 
dialog was loaded. Parameters for cycle detection and Tau fitting options were set as shown in Fig 
2.13. In the Data source pane, the channel 1 exhibiting MAP was used to select 3-5 minutes of 
stable arterial blood pressure for further evaluation. This selected time was marked and then all 
data of this time window including SAP, DAP, MAP, and HR were exported as text file to excel. 
Figure 2.13 The blood pressure setting dialog. 
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Further averaging and evaluation were performed in excel. Left ventricular pressure was 
evaluated in the same manner but further derived parameters EDP, dP/dtmax (the steepest slope 
during the rising pressure curve) and dP/dtmin (the steepest slope during the declining pressure 
curve) were also exported and evaluated in excel.  
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Figure 2.14 Labchart window sheet. (a) The arterial and LV pressure data, (b) the arterial and the 
ventricular cycle. 
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2.4 Light microscopy 
2.4.1.Histology  
2.4.1.1 PFA Fixation 
2.4.1.1.1 Heart cannulation 
 
A petri dish was filled up with the Tyrode’s solution with EGTA (EGTA-Tyrode’s solution in 
mM: 135 NaCl, 4 KCl, 1 MgCl2, 2HEPES, 2.6 EGTA, and 10 glucose and 1 mg/ml BSA; pH 7.4 
(NaOH)) and then a glass rod was fixed with clay at the edge of the petri dish. A loose tie was 
placed around the cannula close to the clay. The cannula was filled up with EGTA-Tyrode’s 
solution and any small air bubbles were removed. After hemodynamic measurement, the mouse 
was euthanized with 4% isoflurane. The sternum was cut and the ribs were cut to open the thorax. 
Then the heart was excised from the thorax and transfered to the EGTA-Tyrode’s solution in the 
prepared petri dish. Under the microscope the aorta was visualized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b a 
c 
Figure 2.15 The heart perfusion. In the Langendorff perfusion system the perfusate flows in a 
retrograde fashion into the aorta. (a) The Langedorff heart perfusion system, (b) schematic drawing of 
the heart and the cannula, (c) the cannulated heart. 
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Two fine curve forceps were used to grab the edge of aorta and to pull the aorta over the cannula. 
The thread was tied around the aorta two times to fix the aorta firmly at the cannula. Finally, the 
cannula with the heart was immediately connected to a Langendorff perfusion system (Fig. 2.15). 
2.4.1.1.2 Perfusion of the heart 
The heart was retrogradely perfused with the above described Tyrode solution with EGTA for 5 
min and then with 4% PFA for 8-10 min. After that the perfused heart was taken off the perfusion 
system and transferred in a 15 ml test tube that was filled up with 4% PFA solution. The heart was 
fixed with the 4% PFA for 24 hours. The heart was dehydrated in a graded series of ethanol (30%, 
50%, and 70%) each step lasted 24 hr. 
2.4.1.2 Automated tissue processor 
The perfused heart was taken out of the test tube and transferred into a labelled cassette. These 
cassettes were mounted in an automated tissue processor (Tissue-Tek®VIPTM 5 Jr, Sakura 
Finetek GmbH, Staufen, Germany). The tissue processor is designed to infiltrate tissue specimen 
with a sequence of differnet solvents melted paraffin wax being the last. In brief, the heart was in 
70% ethanol in the begining (water-based) and passed through multiple changes of dehydration 
and and xylene ending with paraffin. 
2.4.1.3 Paraffin embedding 
The tissue embedding station (Medax GmbH & Co. KG, Neumünster, Germany) was turned on at 
least 1 hour before use. On the heated area, the disposable embedding vessel was filled with 
melted paraffin from a paraffin dispenser. Then vessel was positioned on the cold area of the 
heated plate of the tissue embedding station (Fig. 2.16) in order to produce a small layer of solid 
paraffin at the botom of the the embedding vessel. The heart was picked up in the cassette of the 
automated tissue processor with fine forceps and submersed in the melted paraffin in the 
embedding vessel. It was oriented with the aorta on the top and the apex of heart on the 
bottom.The paraffin block was allowed to solidify in a cold area and then stored at room 
temperature.  
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2.4.1.4 Sectioning with a microtome 
 
 
The Microme HM 355 (Microm GmbH, Walldorf, Germany) (Fig. 2.17) was prepared and the 
water bath was set to 42 °C (Fig. 2.17 a). The heart in the paraffin block was taken off the 
embedment vessel and trimmed by a knife (Microm international GmbH, Walldorf, Germany). 
The knife was heated in the flame of a Bunsen burner. The trimmed block was placed on the 
heated knife and glued to a piece of hardwood by the surface with the melted paraffin. Then the 
paraffin block was secured by melting some small paraffin shavings. Finally the paraffin block 
was allowed to cool down completely (Fig. 2.18). The paraffin block with the heart was mounted 
on the microtome (block holder Fig. 2.17 b) and approached to the knife (Fig 2.17 c). The paraffin 
block was trimmed by cutting off 20 µm sections until the desired level was reached. The section 
thickness was then changed to 5 µm. The ribbon of sections moved a descnding slope to the 
surface of the wather bath. The ribbon of sections floated on water for about 15-30 seconds to 
stretch and to eliminate folds and wrinkles. A microscope slide was then gently immersed into the 
water and the sections were placed on the slide gently to prevent trapping of air bubbles. The 
microscope slides with sections were placed in an oven with 62°C for 6 hours to attach firmly to 
the slides. After that the slides were transferred into a slide box and stored at room temperature.  
 
 
 
Figure 2.16 Tissue embedding station. 
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2.4.1.5 Masson’s Trichrome Staining 
For investigation of the development of cardiac hypertrophy, it is important to differentiate 
between cardiomyocytes and connective tissue in the heart. Therefore it is important to apply a 
staining procedure which stains both tissues in different colors. Masson´s trichrome method 
(Masson-Goldner staining kit, Merck KGaA, Darmstadt, Germany) stains muscle cell red, 
connective tissue green, and cell nuclei black. Therfore we decided for Masson trichrome staining 
to differentiated between the different tissues.  
 
Figure 2.18 Mounting the paraffin block on a piece of hardwood using a heated knife 
Yvan Lindekens. (2007) Making your own paraffin section @home (part2). Weblog. (online) available 
from http://www.microscopy-uk.org.uk/mag/indexmag.html?http://ww.microscopy-
uk.org.uk/mag/artfeb07/yl-para2.html (accessed 6th April 2014). 
a 
b 
c 
Figure 2.17 Microtome. (a) The water bath, (b) the block holder, (c) the knife.  
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First, the microscope slide was placed in the 65 oC oven for 20 min and was allowed to cool down 
for 10 min. Under the hood, the paraffin heart slide was put into Xylene for 5 min two times to 
deparaffinize and then it was rehydrated in a descending series of ethanol (100% for 30 s, 90%, 
80% and 60% each for 3 min). After that the slide was washed in distilled water for 30 s and 
stained in Hematoxylin for 5 min. The slide was taken off from the Hematoxylin and washed in 
ddH2O for 30 s and washed further under running tap water for 5 min. In the next step the slide 
was transferred into 1% acetic acid solution for 30 s, and then was stained in Azophloxin solution 
for 5 min. The slide was then differentiated in 1% acetic acid solution for 30 s. This was followed 
by 1 min in Tungstophosphoric acid orange G solution and a differentiation step of 30 s in 1% 
acetic acid solution. It was then stained in Light green for 4 min and again differentiated in 1% 
acetic acid solution for 30 s. The slide was dehydrated in an ascending series of ethanol (60%, 
80%, 90% and 100% each for 30 s). The slide was put in Isopropanol for 1 min and was cleared 
with Xylene for 1 min. Finally, a drop of Entellan was placed on the slide and a cover slide was 
positioned on the section. This was done by pressing gently onto the cover slide with a pair of 
small forceps to squeeze air bubbles out. The slide was allowed to dry under the hood overnight 
and then stored in a slide box at room temperature. 
 
2.4.1.6 Image analysis and quantification 
 
2.4.1.6.1 LV Thickness 
For quantification of LV thickness the stained heart section was photographed at 10-fold 
magnification. The Image J software was used to analyze LV thickness. In the Image J program 
the scale file was opened. A straight was chosen and used to measure 1 mm length from the scale 
picture. The analyze tab was opened and in the set scale dialog the value from the scale 
measurement was transformed into pixels as demonstrated in Fig 2.19).  
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With these settings a straight was selected in an image file was used to measure the LV thickness 
(Fig. 2.20). To do this the analyze tab opened and measure was chosen. The results were 
displayed automatically and exported to an excel sheet.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19 The image J setting scale. 
Figure 2.20 The left ventricular thickness measurement by Image J. 
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2.4.2 Morphometric mesurements 
The morphometric parameters, body weight (BW), heart weight (HW), left ventricular weight 
(LVW), right ventricular weight (RVW) were evaluated by a KERN accurate scale (KERN & 
SOHN GmbH, Ziegelei 1, 72336 Balingen – Germany) whereas tibia length (TL) was measured 
by a caliper (Fig. 2.21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.3 Immunohistochemical staining of isolated cardiomyocytes 
 
2.4.3.1 Isolation of ventricular cardiomyocytes 
The mouse was weighed and set into the induction chamber, which had been prepared with a 
tissue paper soaked with 2-3 drops of isoflurane. When the mouse had lost consciousness, it was 
taken out of the induction chamber and killed by cervical dislocation. The abdomen was opened 
and then the liver was gently pulled down and the diaphram was cut to open the thoracic cavity 
and expose the heart. Then the heart was excised from the thorax and transferred into the EGTA-
Tyrode’s solution. It was then attached to a Langendorff perfusion system as described in chapter 
a b 
c 
Figure 2.21 The scale and the tibia length measurement. 
(a) The scale, (b) the tibia length, (c) the caliper  
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2.4.1.1.1. The pressure was adjusted to 0.05 bar. The heart was perfused with EGTA-Tyrode’s 
solution for 5-7 min, subsequently, with high-potassium solution (in mM: 4 NaCl, 10 KCl, 130 K-
glutamate, 1 MgCl2, 0.05 CaCl2, 2HEPES, and 10 glucose and 1 mg/ml BSA; pH 7.4 (KOH)) for 
5-6 min. In the next step the perfusion was switched to a high potassium solution supplemented 
with trypsin (0.33 mg/ml trypsin from bovine pancreas (S93610) from Sigma-Aldrich®, 
Steinheim, Germany) for 5 min, followed by pure high-potassium solution for 4-5 min. The last 
perfusing solution was high potassium supplemented with collagenase (0.4 mg/ml; collagenase 
from Clostridium histolyticum Sigma Blend Type L (C8176) from Sigma-Aldrich®, Steinheim, 
Germany). Throughout the procedure, the temperature of the heart was maintained between 35-
36.5°C. After the perfusion the heart was cut into small pieces by scissors and cells were liberated 
from the tissue by mechanical shearing in Tyrode’s solution (in mM: 135 NaCl, 4 KCl, 1.8 CaCl2, 
1 MgCl2, 2HEPES, and 11 glucose and 1 mg/ml BSA; pH 7.4 plus trypsin inhibitor 0.0167 mg/ml 
all from Sigma-Aldrich®, Steinheim, Germany) and then filtered through a nylon mesh (width 125 
µm) into test tubes in order to separate the cells from the debris. After a short spin, the supernatant 
was removed and the pellet was resuspended in 2.5 ml of Tyrode’s solution and allowed to settle 
for 10 minutes at 37°C. After that, the supernatant was removed and cells remaining in the pellet 
were resuspended in ~2.5-3.5 ml of Tyrode’s solution according to the amount of cells. 
Ventricular cardiomyocytes prepared from mice of different genotypes were attached to laminin-
coated microscope slides and fixed with cold -20°C methanol (5 min) and acetone (0.5 min).  
 
2.4.3.2 Immunofluorescence staining of ventricular cardiomyocytes 
 
The cardiomyocytes were stained with antibodies to localize ICD proteins using standard 
procedures. The cardiomyocyte slides were rehydrated, fixed, and frozen in phosphate buffered 
saline (PBS) as usual for 10 minutes. Then the slides were blocked with 10% normal goat serum 
(NGS) in 1%BSA in PBS for 45 minutes at 37°C. After that the blocking solution was removed 
from the slides by tapping. Later the slides were incubated with primary antibody mix at 4°C 
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overnight. The following mixed primary antibodies were used (primary antibodies were diluted in 
1%BSA in PBS): 
1. RR90 10x (Filamin A and C d1-2); 1:5; mouse IgA 
T12 (Titin Z-band epitope); 1:10; mouse IgG1 
CX43 (gap junction); 1:1000; rabbit 
2. CDH (Cadherin); 1:100, rabbit 
T12 (Titin Z-band epitope); 1:10; mouse IgG1 
Mf20 (Myosin HC, all); 1:20, mouse IgG2b 
3. 34C-s (Ryanodine receptors); 1:5; mouse IgG1 
FlnC (FilaminC d16-20); 1:1000, rabbit 
BB78.8 (Myomesin, M-Band); 1:2: mouse IgG2b 
Next, the slides were washed with PBST (PBS with 0.5% Tween) 2 times and then washed in 
PBS 1 time for 5 minutes each. Afterwards, the slides were incubated with mixed secondary 
antibody at 37°C for 2 ½ hours. The following mixed antibodies were used (the secondary 
antibodies were diluted in 1%BSA in PBS): 
1. Goat anti mouse IgG1 Alexa 594,; 1:300 
Goat anti mouse IgA FITC; 1:60 
Goat anti rabbit-Alexa 647; 1.200 
2. Goat anti mouse IgG1 Cy2,; 1:300 
Goat anti mouse IgG2b-Alexa 594; 1:1000 
Goat anti rabbit Alexa 647; 1.200 
3. Goat anti mouse IgG1 Cy2,; 1:300 
Goat anti mouse IgG2A-Alexa 594; 1:1000 
Goat anti rabbit-Alexa 647; 1.200 
Dapi1:40000 were added to mixed secondary antibody. Later on, the slides were washed with 
PBST 2 time and then washed in PBS 1 time for 5 minutes each, respectively. After that, the 
slides were washed with deionized water (ddH2O). Finally, the slides were mounted with a drop 
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of mounting medium (Mowiol with N-propylgalat (1:10) and stored in the dark.  Specimens were 
examined and pictures were acquired using an inverted microscope equipped with fluorescence 
optics (Nikon Eclipse TE-2000-E) and a cooled CCD camera (DVC Company) and Image Pro 
Plus software (Media Cybernetics).  
 
2.5 Statistics 
For statistical analysis, all data were expressed as mean (Mean) and standard error of the mean 
(SEM) was calculated. The computer program Prism 5.0 from GraphPad Software, San Diego, 
USA,  system enabled the rapid determination of statistical significance by one-way ANOVA and 
subsequent post hoc Newmann-Keuls Multiple comparison test. Differences with a level of p 
<0.05 were considered significant. In addition, bar graphs were created displaying the arithmetic 
mean ± SEM. 
 
2.6 Equipments and materials 
 
2.6.1 Animals and materials for animal husbandry 
Products Company 
Animal 
XIRP WT 
XIRP1XIRP2 dko 
 
Institut für Zellbiologie, Bonn University, Germany 
Bedding 
Espen Einstreu ani–bedding 
14 PA animal bedding 
 
AsBe-wood GmbH, Buxtehude, Germany 
Cages 
Makrolon, type II L 
 
Charles River Germany GmbH, Sulzfeld, Germany 
Food 
Standard rodent chow 
V1534-300 
 
Ssniff Spezialdiäten GmbH, Soest, Germany 
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2.6.2 Equipment and materials for the operation  
Products Company 
Equipments 
Body temperature probe Hand-made from an electrical workshop of the Physiological Institute II 
Chest retractors Hand-made from a mechanical workshop of the Physiological Institute 
II 
EKG Hand-made from an electrical workshop of the Physiological Institute II 
Endotracheal tube 
Diameter 1.0 mm and 1.2 
mm 
 
Hugo Sachs Elektronik, March , Hugstetten, Germany 
6-0 Ethicon Prolene  
 
Ethicon, Johnson & Johnson Medical GmbH, Norderstedt, Germany 
Infrared heating bulb 
Infraphil 150w 230v PAR 
38E 
Phillips, Holland 
Isoflurane vaporizer 
Isoflurane Vapor 19.3 
 
Dräger, Medizintechnik GmbH, Lübeck, Germany 
Mouse ventilator 
MiniVent Type 845 
 
Hugo Sachs Elektronik 
Operation stage 
Water circulation system 
 
Hand-made from a mechanical workshop of the Physiological Institute 
II 
Surgical instruments 
curve scissor, mosquito 
clamp, fine curve forceps, 
cubic curve forceps, and 
needle holder 
 
Allgaier instrumente GmbH, Frittlingen/Tuttlingen, Germany 
Surgical microscope  
OPMI 1FR pro 
Carl Zeiss Surgical GmbH, Oberkochen, Germany  
USP 5/0 
Seraflex® 
 
Serag-Wiessner KG, Naila, Germany 
Water bath 
Haake Model L Waterbath 
with D8 Circulator 
 
Haake, Germany 
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Products Company 
Chemical 
Analgesic 
Buprenorphine Temgesic®  
(Buprenorphine hydrochloride 
0.324mg/ml) 
 
Reckitt Benckiser (Deutschland) GmbH, Mannheim, Gremany 
Anesthesia 
Isofluran: Forene® 
 
Abbott GmbH & Co. KG, Wiesbaden, Germany 
Ethanol 70% Otto Fischar GmbH & Co. KG, Saarbrüchen, Germany 
Eye ointment  
Bepanthen® 
Bayer vital GmbH, Leverkusen, Germany 
Povidone-iodine 
Betaisodona Lösung® 
 
Mundipharma GmbH, Limburg, Germany 
 
2.6.3 Equipment and materials for the hemodynamic measurement  
Products Company 
Computer HP Compaq dc 7900, Hewlett-Packard Development Company, 
Germany 
LabChart  
Chart v6.0 for Windows 
  
ADInstruments Ltd, Spechbach, United Kingdom 
Pressure catheter  
Ultra-Miniature Pressure 
Catheter 
 Transonic System Inc, NW Maastricht, Netherlands 
Pressure Control Unit 
FP095B – Dual channel 
Pressure Control Unit 
Version 095B-01 
 Transonic System Inc 
Power lab 8SP  ADInstruments Ltd, Spechbach, Germany 
Surgical instruments 
curve scissor, mosquito 
clamp, fine curve forceps, 
cubic curve forceps, and 
fine vannas scissor 
 
Allgaier Instrumente GmbH, Frittlingen/Tuttlingen, Germany 
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2.6.4 Equipment for histology 
Products Company 
Equipments 
Blade 
Einwegklinge SEC 35 
(152200) 
 
Microm international GmbH, Walldorf, Germany 
 
Cassette 
Einbettkassetten Macro 
E478.1 
 
Karl Roth GmbH Co. KG, Karlsruhe, Germany 
Cover slips 
24 x 60 mm 
 
Gerhard Menzel GmbH, Braunschweig, Germany 
Disposable paraffin molds 
Peel-A-Way® Embedding 
Mold (Square – S22) 
 
Polysciences Europe GmbH, Eppelheim, Germany 
Image J 
V 1,47 
 
Wayne Rasband , National Institutes of Health , USA 
Microscope slide 
SuperFrost® Plus 
 
Gerhard Menzel GmbH, Braunschweig, Germany 
Microtome 
The Microme HM 355 
  
Microm GmbH, Walldorf, Germany 
Paraffin dispenser Medax GmbH & Co. KG, Neumünster, Germany 
The automated tissue 
processor 
 Tissue-Tek®VIPTM 5 Jr, Sakura Finetek GmbH, Staufen, Germany 
Chemical  
Hematoxynlin solution 
HHS32-1L 
 
Sigma-Aldrich®, Missouri, UAS 
Masson-Goldner staining 
kit 100485 
Merck KGaA, Darmstadt, Germany 
Paraformaldehyde Sigma-Aldrich®, Missouri, UAS 
2-Propanol Merck KGaA 
Rapid mounting medium 
for microscopy 
Entellan® 
 
 
Merck KGaA 
Xylene VWR®, Lueven, Belgium 
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2.6.5 Immunohistochemistry staining 
Products Company 
Equipments 
Langendorff heart 
perfusion system 
Hand-made from a mechanical workshop of the Physiological Institute 
II 
Mowiol Sigma-Aldrich®, Steinheim, Germany 
Chemical 
Antibody 
RR90 (Filamin A and C 
domain 1-2) 
Cx43 (Connexin43) 
T12 (Titin, z-band) 
Mf20 (Myosin HC) 
FlnC 16-20  
(FilaminC d16-20) 
BB78  
(Myomesin domain 12 (m-
band)) 
34C-s  
(α,β ryanodine receptors) 
CDH (cadherin) 
Alexa Dy 594en 
DAPI 
Alexa 647 
IgA-FITC GAM   
IgG2a-Alexa 594 
IgA-FITC GAM   
IgG2b-Alexa 594 
IgG1-Cy2 
 
 
Van der ven et al., 2000 
AG Willecke 
Fürst et al., 1988 
 
dshb 
AG Fürst 
 
 
Vinkemeier et al., 1993 
 
dshb 
Sigma, Germany 
SBA 
Invitrogen 
Jackson 
Invitrogen 
Molecular probes 
Invitrogen 
Molecular probes 
Invitrogen 
BSA 
Bovine Serum Albumin  
 
Sigma-Aldrich®, Steinheim, Germany 
CaCl2 * 2 H2O 
Calcium chloride dihydrate 
 
Merck KGaA 
Collagenase 
(from Clostiridium 
histolyticum, Sigma Blend 
Type L, ≤1.0 FALGPA 
units/mg solid)  
 
Sigma-Aldrich® 
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Products Company 
Chemical 
D(+)-Glucose 
monohydrate 
Merck KGaA 
HCl 
Hydrochloric acid solution 
(1 mol/ l) 
Merck KGaA 
 
  
HEPES 
2-(4-(2-Hydroxyethyl)-1-
piperazinyl)- ethanesulfonic 
acid, buffer substance 
Merck KGaA 
KCl 
Potassium chloride 
Merck KGaA 
KOH 
Potassium hydroxide 
solution 
(1 mol/ l) 
Merck KGaA 
Laminin Sigma-Aldrich® 
L-glutamate Potassium Sigma-Aldrich® 
MgCl2 * 6 H2O 
Magnesium chloride 
hexahydrate 
Merck KGaA 
NaCl 
Sodium chloride 
Merck KGaA 
NaOH 
Sodium hydroxide solution 
(1 mol/ l) 
Merck KGaA 
Trypsin  
(from bovine pancreas, 
essentially salt free, 
lyophilized, ~9000 U/mg) 
Sigma-Aldrich® 
Trypsin inhibitor 
(from Glycine max 
(soybean), powder,  
BioReagent, suitable for 
cell culture) 
Sigma-Aldrich® 
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2.6.6 Others 
Products Company 
Caliper Mauser , St. Denis , France 
Scale 
1. The coarse digital scale 
2. The fine digital scale 
 
 Kern EMB 500-1, Precision balance, KERN & SOHN, Balingen, 
Germany 
Faust GmbH, Germany 
Terg-A-Zyme 
protease enzyme for 
presoaking proteinaceous 
soils and hard-to-remove 
stains 
 
Alconox Inc., New York, USA 
GraphPad Prism 5 Graphpad Inc., La Jolla, CA, USA 
Ultra-Tiefkühlschrank  
(-80C°) 
Doubaras GmbH, Düsseldorf, Germany 
 
 
 
 
  
3 Results 
3.1 Animals 
3.1.1 Animal numbers 
A total of XIRP female 135 animals were examined. 39 XIRP WT mice (17 Sham and 22 TAC), 
which served as control animals for XIRP1XIRP2dko mice, were compared to 96 XIRP1XIRP2 
dko mice (40 Sham and 56 TAC).  
 
3.1.2 Mortality rate 
In this study the mortality from immediately after TAC or sham surgery until the end of the 
experiments 14 days later - depending on the group - amounted to 0% in both sham groups, 10% 
in the XIRP WT, 16.2 % in XIRP1XIRP2 dko, The low mortality rates in these groups show that 
the surgeries were performed in a professional manner. 
 
3.1.3 Age of the mice 
The mice were age matched and there was no statistically significant difference between the 
groups at the day of the surgery (XIRP WT 13.5 ± 0.2 weeks old; XIRP1XIRP2 dko 13.0 ± 0.2 
weeks old). In addition to the 13 weeks old mice, a group of 1 year old mice was investigated 
(XIRP WT 13.1 ± 0.1 months old; XIRP1XIRP2 dko 12.0 ± 0.3 months old). 
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3.1.4 Characterization of protein expression of the mouse model 
As mentioned above, in the center of this investigation are mice, which are XIRP1 deficient and 
do not express any of the three XinABC-/- isoforms and which are hypomorphic for XIRP2. In 
order to define the genetic status of these mice, the expression of the XIRP1 and XIRP2 genes was 
investigated by Western blot. The proteins XIRP2, XinA, XinB and myomesin were monitored on 
protein extracts from whole hearts of WT and XIRP1XIRP2 dko mice Fig 3.1. 
In WT mice the three Xin-repeat proteins as well as myomesin could be detected. In 
XIRP1XIRP2 dko mice the three Xin-repeat proteins could not be demonstrated, but myomesin 
was present in comparable amount as in WT-mice. 
 
Subsequently, cryosections of myocardial tissue from XIRP WT and XIRP1XIRP2 dko were 
investigated by immunofluorescence microscopy. In first series, antibodies against the proteins 
XIRP2, filamin A and C as well as vinculin were applied together. In WT mice the four proteins 
could be demonstrated in the ICDs, where they all co-localized (Fig. 3.2). In a second series, 
antibodies against XIRP1, filamin A and C as well as α-actinin were incubated on the 
Figure 3.1 Western-blot analysis of whole hearts from WT and XIRP1XIRP2 dko mice. Each lane 
represents one animal. 
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Figure 3.2 Fluorescence microscopic visualization of immunofluorescence stainings in cryosections of 
hearts from XIRP WT and XIRP1XIRP2 dko mice (scale 2µm). 
cryosections of WT hearts. XIRP1 and the filamins were shown on the ICDs, whereas the α-
actinin antibody appeared in the typical cross-striation pattern of cardiac muscle. The merged 
pictures showed a common localization of the proteins in the Z-disks as well as in the ICDs (Fig. 
3.2).  
Application of antibodies against XIRP1 and XIRP2 and filamin A and C to cryosections of 
XIRP1XIRP2 dko hearts did only lead to binding of the filamin antibodies at the ICDs. 
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3.1.5 Body weight of the mice 
The body weight (BW) of XIRP WT and XIRP1XIRP2 dko mice did not differ significantly at 13 
weeks of age (23.2 ± 0.6 g; n = 10 vs 22.8 ± 0.4 g; n = 23). For comparison, a group of age 
matched C57BL/6 mice (the most widely used mice for experiments) was added to the bar graph 
(average age 13.2 ± 0.1-weeks, BW 20.6 ± 0.5 g, n= 17). The C57BL/6 mice were significantly 
more lightweight.  
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Figure 3.3 Body weight (BW) of the mice of all genotypes. The BW did not differ between the 
XIRP WT and the XIRP1XIRP2 dko, but age matched C57BL/6 mice were significantly more 
lightweight. The data are represented as mean ± SEM; n= 10-23 /group, ***P< 0.001. 
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3.1.6 Tibia length of the mice 
The tibia length (TL) of XIRP1XIRP2 dko mice was significantly longer than that of XIRP WT 
mice 13 weeks of age (16.42 ± 0.06 mm; n = 52 vs 15.77 ± 0.1 g; n = 27). For comparison a group 
of age matched C57BL/6 mice was added to the bar graph (average age 13.2 ± 0.1-weeks, TL 
16.05 ± 0.08 mm, n= 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.7 HW, HW/BW ratio, and HW/TL ratio  
Like in the case of BW, also the heart weights (HW) of the two genotypes of mice did not differ 
significantly (XIRP WT 130.9 ± 3.6 g n = 11 vs XIRP1XIRP2 dko 127.1 ± 3.5 g n = 23). Also the 
normalized ratios of heart weight/body weight (HW/BW ratio; XIRP WT 5.64 ± 0.08 mg/g n = 11 
vs XIRP1XIRP2 dko 5.57 ± 0.11 mg/g n = 23) and heart weight/tibia length (HW/TL ratio; XIRP 
WT 8.23 ± 0.19 mg/mm n = 11 vs XIRP1XIRP2 dko 7.7 ± 0.2 mg/mm n = 23) were statistically 
not different. 
Figure 3.4 The tibia length (TL) of the mice of all genotypes, the TL of XIRP1XIRP2 dko were 
significantly longer than Xin WT and C57BL/6 mice. The data are represented as mean ± SEM; 
n= 27-53/ group, ***P< 0.001. 
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3.1.8 LVW, LVW/BW ratio, and LVW/TL ratio  
In case of differences in the systemic circulation between the two genotypes a comparison of left 
ventricular weights is more meaningful, therefore these data are demonstrated here. Neither left 
ventricular weight (LVW) nor the LVW/BW ratio nor the LVW/TL ratio differed significantly 
between the genotypes, but LVW/TL was with P = 0.054 close to the level of significance (XIRP 
WT n = 6 vs XIRP1XIRP2 dko n = 9: LVW 96.5 ± 3.19 g vs 90.3 ± 4.17 g; LVW/BW ratio 4.27 
± 01.19 mg/g vs 3. 94 ± 0.13mg/g; LVW/TL ratio 6.19 ± 0.22 mg/mm vs. 5.5 ± 0.22 mg/mm).  
Figure 3.5 HW, HW/BW ratio and HW/TL ratio of XIRP WT and XIRP1XIRP2 dko mice. Both 
genotypes did not differ significantly in HW, HW/BW ratio, and HW/TL ratio. The data are represented 
as mean ± SEM; n= 11-30 /group. 
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3.1.9 LW, LW/BW ratio, and LW/TL ratio 
The lung weight (LW) is an important parameter which may differ in case of increased EDP in 
the left ventricle. This leads to a congestion of blood in the lungs. Therefore the lung weight was 
detected in both genotypes. Neither LW nor the LW/BW ratio were significantly different 
between the genotypes, but the LW/TL ratio was with P = 0.034 significantly different (XIRP WT 
n = 11 vs XIRP1XIRP2 dko n = 23: LW 150.8 ± 3.04 g vs 144.4 ± 3.89 g; LVW/BW ratio 6.53 ± 
0.17 mg/g vs 6.32 ± 0.11 mg/g; LVW/TL ratio 9.5 ± 0.23 mg/mm vs. 8.75 ± 0.21 mg/mm).  
Figure 3.6 LVW, LVW/BW ratio, LVW/TL ratio of XIRP WT and XIRP1XIRP2 dko mice. LVW, 
LVW/BW ratio, and LVW/TL ratio did not differ significantly between both genotypes. The data are 
represented as mean ± SEM; n= 6-9 /group. 
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Taken together, in the macroscopic anatomic parameters there were only minor differences 
between both genotypes compared in this study. In the following chapters all investigated 
parameters will be demonstrated in conjunction with the results of the TAC surgery.  
 
 
 
 
Figure 3.7 LW, LW/BW ratio, LW/TL ratio of XIRP WT and XIRP1XIRP2 dko mice. LW/TL ratio 
was significantly smaller in XIRP1XIRP2 dko than in XIRP WT, whereas LW and LW/BW ratio 
were equal. The data are represented as mean ± SEM; n= 11-23 /group. 
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Table 3.1   Development of BW from the operation to the measurement day 
3.2 The effect of TAC surgery 
3.2.1 The effect of surgery on BW 
To evaluate the influence of the surgery on the BW, it was measured at the date of surgery and 
sacrifice. Subsequently the BW-difference was calculated. This development of body weight is 
demonstrated in table 3.1. Except in the XIRP1XIRP2 dko sham group, in which the weight 
stayed nearly stable, all other groups gained a small amount of weight, which did not reach the 
level of significance. 
 
 
Genotype Treatment n BW-OP BW-ME BW-difference 
XIRP WT  Sham 14d  10 23.1 ± 0.6 23.4 ± 0.6 0.3 ± 0.4 
XIRP WT TAC 14d 13 23.0 ± 0.8 23.3 ± 0.7 0.4 ± 0.3 
XIRP1XIRP2 dko  Sham 14d 23 22.9 ± 0.6 22.8 ± 0.5 -0.0 ± 0.3 
XIRP1XIRP2 dko TAC 14d 30 23.4 ± 0.5 24.1 ± 0.4 0.7 ± 0.3 
 
 
 
 
  
Results are means ± SEM; n, number of animals. BW-OP: body weight on the day of the surgery,
BW-ME: body weight on the day sacrifice, BW-difference: (BW-ME)-(BW-OP), statistically non-
significant difference (P< 0.05) by all groups comparison.  
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3.2.2 HW, HW/BW ratio, and HW/TL ratio 
14 days of TAC induced a significant increase in all three heart weight parameters HW, HW/BW 
ratio, and HW/TL ratio in both genotypes (Fig. 3.8 A, B, and C). However, differences between 
the genotypes could not be detected (XIRP WT: sham HW 130.9 ± 3.7 mg vs TAC HW 163.7 ± 
6.1 mg; sham HW/BW ratio 5.6 ± 0.1 mg/g vs. TAC HW/BW ratio 6.8 ± 0.2 mg/g; sham HW/TL 
ratio 8.2 ± 0.2 mg/mm vs. TAC HW/TL ratio 10.4 ± 0.3 mg/mm; XIRP1XIRP2 dko: sham HW 
127.1 ± 3.5 mg vs. TAC HW 171.0 ± 3.9 mg; sham HW/BW ratio 5.6 ± 0.1 mg/g vs. TAC 
HW/BW ratio 7.1 ± 0.2 mg/g; sham HW/TL ratio 7.7 ± 0.2 mg/mm vs TAC HW/TL ratio 10.5 ± 
0.3 mg/mm). 
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Figure 3.8 HW, HW/BW ratio, HW/TL ratio of XIRP WT and XIRP1XIRP2 dko mice. HW, 
HW/BW ratio, and HW/TL ratio were significantly increased in TAC group of both genotypes. The 
data are represented as mean ± SEM; n= 11-30 /group, *P< 0.05 was considered statistically 
significant. 
72 
 Results 
 
73 
3.2.3 LVW, LVW/BW ratio, and LVW/TL ratio 
As shown already for the HW parameters, also the LVW parameters were significantly increased 
by TAC (Fig. 3.9 A, B, C). But again the influence of TAC did not differ between both genotypes 
(XIRP WT: sham LVW 96.5 ± 3.2 mg vs TAC LVW = 117.7 ± 4.9 mg; sham LVW/BW ratio 4.3 
± 0.1 mg/g vs TAC LVW/BW ratio 5.0 ± 0.1 mg/g; sham LVW/TL ratio 6.2 ± 0.2 mg/mm vs. 
TAC LVW/TL ratio = 7.6 ± 0.3 mg/mm; XIRP1XIRP2 dko: sham LVW = 90.3 ± 4.2 mg vs. TAC 
LVW = 126.4 ± 5.1 mg; sham LVW/BW ratio = 4.0 ± 0.1 mg/g vs TAC LVW/BW ratio = 5.1 ± 
0.2 mg/g; sham LVW/TL ratio = 5.5 ± 0.2 mg/mm vs TAC LVW/TL ratio = 7.8 ± 0.3 mg/mm). 
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3.2.4 LW, LW/BW ratio, and LW/TL ratio  
Figure 3.9 LVW, LVW/BW ratio, LVW/TL ratio of XIRP WT and XIRP1XIRP2 dko mice. LVW, 
LVW/BW ratio, and LVW/TL ratio were significantly increased in the TAC groups to the same level 
in both genotypes. The data are represented as mean ± SEM; n= 6-9 /group, *P< 0.05 was considered 
statistically significant. 
 Results 
 
3.2.4 LW, LW/BW ratio, and LW/TL ratio 
14 days of TAC also significantly increased the lung weight parameters in both genotypes. 
However, in this case all lung weight parameters of XIRP1XIRP2 dko exhibited a tendency to 
lower values after TAC, reaching the level of significance only in case of LW/TL ratios (Fig. 3.10 
A, B, C) (XIRP WT: sham LW 150.8 ± 3.0 mg vs TAC LW 176.3 ± 7.3 mg; sham LW/BW ratio 
6.5 ± 0.2 mg/g vs TAC, LW/BW ratio 7.3 ± 0.2 mg/g; sham LW/TL ratio 9.5 ± 0.2 mg/mm vs. 
TAC LW/TL ratio 11.2 ± 0.4 mg/mm; XIRP1XIRP2 dko: sham LW 144.4 ± 3.9 mg vs TAC LW 
166.1 ± 4.8 mg; sham LW/BW ratio 6.3 ± 0.1 mg/g vs TAC LW/BW ratio 6.9 ± 0.2 mg/g; sham 
LW/TL ratio 8.8 ± 0.2 mg/mm vs TAC LVW/TL ratio 10.1 ± 0.3 mg/mm).  
 
 
Figure 3.10 LW, LW/BW ratio, LW/TL ratio of XIRP WT and XIRP1XIRP2 dko. TAC 
increased all LW parameters in both genotypes. But LW/TL ratio was increased in XIRP WT to a 
higher level than in XIRP1XIRP2 dko mice. The data are represented as mean ± SEM; n= 11-30 
/group, *P< 0.05 was considered statistically significant 
0
50
100
150
200
LW
sham
TAC
*** ***
XIRP WT XIRP1XIRP2 dko
LW
 
[m
g]
0
2
4
6
8
LW/BW
XIRP WT XIRP1XIRP2 dko
* *
LW
/B
W
 
[m
g/
g]
0
5
10
15
* **
*
LW/TL
XIRP WT XIRP1XIRP2 dko
LW
/T
L 
[m
g/
m
m
]
A B
C
74 
 Results 
 
75 
3.2.5 Left ventricular and septum thickness 
To investigate the influence of the genotype and the TAC on cardiac morphology, sections of the 
heart were analyzed for left ventricular thickness and thickness of the septum. LV and septum 
thickness did not differ between sham mice of both genotypes (Fig. 3.11, 3.12). Furthermore TAC 
induced a significant growth of LV and septum thickness in both mouse strains But did not reveal 
any differences between the two genotypes in these parameters (LV thickness: XIRP WT sham 
0.56 ± 0.03 mm vs. TAC 0.98 ± 0.11 mm; XIRP1XIRP2 dko sham; 0.63 ± 0.03 mm vs. TAC 0.99 
± 0.08 mm; septum thickness: XIRP WT sham 0.57 ± 0.03 mm; XIRP WT TAC 1.0 ± 0.1 mm; 
XIRP1XIRP2 dko sham 0.65 ± 0.06 mm; XIRP1XIRP2 dko TAC 0.98 ± 0.08 mm).  
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Figure 3.11 Comparison of septum thickness between XIRP1XIRP2 dko and XIRP WT.    
TAC induced a significant increase in septum thickness reaching the same level in both genotypes. 
The data are represented as mean ± SEM; n= 6-11 /group, *P< 0.05 was considered statistically 
significant. 
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3.2.6 Fibrosis 
Fibrosis was analyzed on cross sections of the cardiac ventricles which were stained by Masson’s 
trichrome. A set of photographs at different magnifications of sham and TAC mice is 
demonstrated in Fig. 3.12. The pictures were chosen to give an impression of the interstitial 
fibrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Light microscopic photographs of transverse sections of hearts trichrome stained 
according to Masson from the four groups. (A) Low magnification exhibiting the complete 
sections. (B-D) Representative photographs demonstrating the interstitial fibrosis visualized by 
Masson’s trichrome staining in increasing magnifications (scale bar is 500 µm).  
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In Figure 3.13 the aspect of perivascular fibrosis is emphasized. Perivascular fibrosis was mainly 
found in TAC mice.  
 
In order to quantify the influence of the TAC and the genotype on the development of fibrosis, 
photographs demonstrated in Figs. 3.12 and 3.13 were evaluated for the area of fibrosis. This 
quantification revealed that TAC increased fibrosis in XIRP WT hearts significantly (from 0.17 ± 
0.09 % to 4.0 ± 1.1 %). Although an increase of fibrosis was also visible in the XIRP1XIRP2 dko 
TAC group, this did not reach the level of significance, which is obviously due to a relatively high 
variation in this group. This high variation also prevented to demonstrate a significant difference 
between the two TAC groups, which seemed to be visible. 
  
Figure 3.13 Light microscopic photographs of transverse sections of hearts trichrome stained 
according to Masson from the four groups. (A-C) Representative photos of perivascular fibrosis in 
increasing magnifications (scale bar is 500 µm).   
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3.3  Studies on isolated cardiomyocytes  
3.3.1 Immunolocalization of different proteins 
According to the published role of XIRPs as proteins of the cytoskeleton, the deficiency of these 
proteins might cause mislocalization of other cytoskeletal proteins. Therefore, a selection of 
proteins was visualized in isolated cardiomyocytes by immunofluorescence microscopy 
(performed by Julia Schuld). Cardiomyocytes isolated from XIRP WT sham and TAC and from 
XIRP1XIRP2 dko sham and TAC hearts were investigated. The cells were stained with antibodies 
of proteins found in ICDs (connexin43, cadherin) or in Z bands (titin) and M bands (myomesin). 
The cytoskeletal proteins filamin (Fln) A and C were localized with antibodies binding to both 
(A/C, Ig-like domains 1-2) and to filamin C exclusively (C, Ig-like domains 16-20) 3.16, and 
3.17). Furthermore, the ryanodine receptors (RyRs) were stained as indicators for the triads and 
the nuclei were marked with Dapi. In the first series myomesin, RyRs, Fln C and nuclei were 
Figure 3.14 Quantified area of fibrosis in sham and TAC hearts of both genotypes. The cardiac 
interstitial fibrotic area was significantly increased in XIRP WT TAC vs. sham hearts of both 
genotypes. The data are represented as mean ± SEM; n= 4-7 /group, *P< 0.05 was considered 
statistically significant. 
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stained (Fig. 3.15). Myomesin, RyRs and FlnC display a striation pattern in the cytoplasm and the 
area of the nuclei appears dark. 
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 Results 
 
Fln C is also detected in the regions of the ICDs. Myomesin and Fln C seem to co-localize in their 
striation pattern and at the ICDs, whereas RyRs are found in the gaps between these stripes. A 
basic difference between the four groups could not be detected. 
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In a second set of stainings, antibodies (ABs) against Fln A/C, titin (Z-lines) and connexin (Cx) 
43 were applied. The Fln A/C and the Cx 43 ABs were concentrated in the regions of the ICDs, 
where they co-localized. The titin AB exhibited the regular striation pattern of the Z lines. Again 
an obvious influence of the genotype and the treatment (sham or TAC) could not be detected. In a 
M
er
ge
 
D
ap
i 
Ca
dh
er
in
 
Ti
tin
 
(Z
-
lin
es
) 
Fl
n
A/
C 
d1
-
2 
X
IR
P
 W
T
 s
h
a
m
 
X
IR
P
 W
T
 T
A
C
 
X
IR
P
1
X
IR
P
2
 d
k
o
 
X
IR
P
1
X
IR
P
2
 d
k
o
  
Fi
gu
re
 
3.
17
 
M
ic
ro
sc
o
pi
c 
ev
al
u
at
io
n
 
an
d 
im
m
u
n
o
lo
ca
liz
at
io
n
 
o
f f
ila
m
in
A
/C
 
d1
-
2,
 
tit
in
,
 
an
dc
ad
he
rin
 
in
 
is
o
la
te
d 
ca
rd
io
m
yo
c
yt
es
.
 
 
 Results 
 
third series, ABs against Fln A/C, titin (Z-line) and cadherin were tested. Cadherin was detected 
in the same regions as the Cx 43 ABs in the experiment before. Also in the experiments with 
cadherin ABs, neither the genotypes nor the treatments caused an obvious difference in the 
distribution of the investigated proteins. 
 
3.3.2 Cell size of cardiomyocytes  
To check the influence of cardiac hypertrophy, the length and width of isolated cardiomyocytes 
were measured. XIRP WT sham (n=100), XIRP WT TAC (n=56), XIRP1XIRP2 dko sham 
(n=52), and XIRP1XIRP2 dko TAC (n=74). The length of the cells did not differ in XIRP WT 
groups. Interestingly XIRP1XIRP2 dko sham exhibited a significantly higher length than 
XIRP1XIRP2 dko TAC cells. Moreover, the XIRP1XIRP2 dko sham also were significantly 
longer than XIRP WT sham cells (cell length; XIRP WT sham 122.1 ± 2.5 µm, TAC 114.7 ± 3.4 
µm; XIRP1XIRP2 dko sham 134.3 ± 3.0 µm, TAC 123.4 ± 2.8 µm). The width of the 
Figure 3.18 Cardiomyocyte length and width. 
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XIRP1XIRP2 dko cardiomyocytes reached significantly higher values after TAC, whereas the 
XIRP WT cardiomyocytes exhibited only a trend to transversal growth (XIRP WT sham 22.2 ± 
0.7 µm, TAC 23.2 ± 0.7 µm; XIRP1XIRP2 dko sham 18.8 ± 0.7 µm; XIRP1XIRP2 dko TAC 
24.1 ± 0.7 µm) (Fig. 3.18). 
 
3.3.3 The distribution of ICDs 
ICD-associated proteins were analysed by immunofluorescence microscopy. Staining for cadherin 
and connexin43 demonstrated that XIRP WT and XIRP1XIRP2 dko cells contained same 
amounts of terminal ICDs, while the number of non- terminal ICDs was significantly increased in 
XIRP WT sham and XIRP WT TAC cells (terminal ICDs; XIRP WT sham 3.0 ± 0.1; XIRP WT 
TAC 2.8 ± 0.1; XIRP1XIRP2 dko sham 3.3 ± 0.2; XIRP1XIRP2 dko TAC 3.1 ± 0.1 and non-
terminal ICDs; XIRP WT sham 4.7 ± 0.3; XIRP WT TAC 5.1 ± 0.3; XIRP1XIRP2 dko sham 3.4 
± 0.2; XIRP1XIRP2 dko TAC 3.36 ± 0.2) (Fig. 3.19). 
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Figure 3.19 The single cardiomyocyte and number of terminal and non-terminal ICDs. 
A) The single cardiomyocytes in all groups 
B) The number of terminal and non-terminal ICDs of XIRP WT and 
XIRP1XIRP2 dko 
C) The number of terminal and non-terminal ICDs of XIRP WT and 
XIRP1XIRP2 dko after 14 days TAC 
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3.4 Hemodynamic parameters 
3.4.1 Hemodynamic data after 14 days TAC 
TAC surgery significantly increased systolic arterial pressure (SAP) and left ventricular systolic 
pressure (LVSP) by 50-60 mmHg, which reached comparable levels in mice of both genotypes. 
DAP was not increased XIRP WT mice. This indicates successful aortic banding In XIRP1XIRP2 
dko mice DAP even showed a trend to decrease. The end-diastolic pressure (EDP) showed a trend 
to increase in TAC mice and reached the level of significance in XIRP1XIRP2 dko mice. The 
dP/dt max as well as dP/dt min became faster in both genotypes due to TAC, and dP/dt max rose 
significantly more in XIRP WT than XIRP1XIRP2 dko mice. This may be taken as a sign for a 
compensated hypertrophy. Heart rate (HR) was also significantly increased in both TAC groups 
by 16% in XIRP WT and by 8% in XIRP1XIRP2 dko (Fig. 3.20 A, B, C, D, E, F and Table. 3.2).  
 
Table 3.2   The hemodynamic data of XIRP WT and XIRP1XIRP2 dko mice 
 
XIRP WT XIRP1XIRP2 dko 
 
Sham TAC Sham TAC 
n (number of the mice) 7 11 23 27 
SAP (mm Hg) 107.5 ± 2.0 160.3 ± 4.5 a 104.1 ± 2.0 156.8 ± 2.2 a 
DAP (mm Hg) 78.7 ± 2.5 83.0 ± 1.1 b 78.1 ± 1.8 73.9 ± 1.2 
MAP (mm Hg) 90.2 ± 2.4 113.8 ± 1.9 a 88.5 ± 1.5 108.7 ± 1.2 a 
LVSP (mm Hg) 106.8 ± 3.6 158.8 ± 5.1 a 99.3 ± 2.6 156.6 ± 1.8 a 
EDP (mm Hg) 8.8 ± 1.6 12.1 ± 2.1 6.7 ± 1.0 13.2 ± 0.1 a 
LV dP/dt max (mm Hg/s) 9470.7 ± 583.8 11739.5 ± 610.1 a 8570.8 ± 248.8 9729.2 ± 349.3 a 
LV dP/dt min (mm Hg/s) -10525.1 ± 535.2 -12255.7 ± 767.6 a -9651.5 ± 382.5 -11044.2 ± 381.0 a 
HR (beat/min) 509.3 ± 11.6 590.3 ± 12.6 a 535.7 ± 11.8 576.1 ± 6.5 a 
All values are shown as means ± SEM for n mice. SAP (systolic arterial pressure), DAP (diastolic arterial 
pressure), MAP (mean arterial pressure), LVSP (left ventricular systolic pressure), EDP (end diastolic 
pressure), dP/dt max  (maximum left ventricular dP/dtmax, dP/dtmin  (the minimum left ventricular dP/dt), HR 
(heart rate). a; P< 0.05 vs sham b; P< 0.05 vs XIRP1XIRP2 dko TAC 
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Figure 3.20 Hemodynamic data of XIRP WT and XIRP1XIRP2 dko female after TAC. (A, B) TAC 
surgery increased SAP and LVSP in both genotypes by about the same degree. (C) EDP was also 
increased in TAC mice of both genotypes. (D) HR was significantly elevated in both TAC groups. 
(E, F) dP/dtmax as well as dP/dtmin became faster in both genotypes due to TAC. dP/dtmax of XIRP 
WT TAC mice reached significantly higher level than that of  XIRP1XIRP2 dko TAC mice. The 
data are represented as mean ± SEM; n= 8-29 /group, *P< 0.05 was considered statistically 
significant.  
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3.5 Electrocardiogram  
An electrocardiogram (ECG) allows detection of the electrical excitation of the heart. In this 
study, the surface ECG lead II according to Einthoven was recorded. In Fig 3.21 the coupling of 
the electrodes is presented in man and mouse. Lead II means that the voltage difference between 
the right arm and the left leg is monitored. The typical recordings from man and mouse are shown 
in Fig. 3.21 B. Due to the high heart rates and the small size of the mice, the shape of both ECG 
differs remarkably. The ECGs were recorded under anesthesia (1% isoflurane) in sham and TAC 
mice of both genotypes.  
 
 
A 
B C 
Figure 3.21 The ECG of a human and a mouse. 
(A) Schematic drawings of the positions of the leads R, L and F in humans and mice and the triangle 
of Einthoven respectively (B) Schematic representation of the human and murine ECG (C) Schematic 
standard ECG lead II. (Slightly modified from Boukens et al., 2014) 
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Abnormal ECGs were not found in recordings from XIRP WT mice neither in the sham nor in the 
TAC group. In contrast, ECG recordings from XIRP1XIRP2 dko TAC mice exhibited an irregular 
HR and missing P waves in 9.0%, biphasic (bifid) p-waves in 18.2%, and ST elevations in 4.6% 
of the recordings, while the XIRP1XIRP2 sham mice ECG recordings developed biphasic P 
waves in 38.5% of the recordings.  
 
3.5.1 Surface ECG parameters 
ECG records were non-invasively obtained from 1% isoflurane anesthetized mice on the 
measurement day. HR, P wave, PQ interval, QRS duration and QT interval are summarized in 
Table 3.3. In both genotypes there was a tendency to an increased HR in the TAC groups but the 
level of significance was not reached. P wave duration, PQ interval as well as QT interval were 
significantly prolonged in XIRP1XIRP2 dko TAC mice compared to their respective controls.  
In the XIRP WT TAC mice there was a tendency to prolongation in P wave duration and PQ 
interval compared to their controls. Also the QRS complex and the QT interval showed trend to 
prolongation in the TAC groups. QT interval was longer both TAC genotypes compared to their 
controls, reaching significance level in the XIRP1XIRP2 dko mice. The tendency prolongation of 
Table 3.3   Surface ECG parameters 
 
XIRP WT 
sham 
(n=6) 
 XIRP WT 
TAC 
(n=5) 
 XIRP1XIRP2 
dko 
sham 
(n=15) 
 XIRP1XIRP2 
dko 
TAC 
(n=20) 
Heart rate (bpm) 517.0 ± 8.5   563.3 ± 25.1  508.1 ± 14.4  520.1± 13.4 
P duration (ms) 15.2 ± 1.2  18.0 ± 0.8  14.1 ± 1.2  19.5 ± 0.8a,b 
PQ (ms) 29.2 ± 0.7  34.4 ± 1.4  32.5 ± 0.4  38.6 ± 1.2a,b 
QRS (ms) 11.3 ± 1.1  12.3 ± 1.1  9.6 ± 0.2b  11.0 ± 0.4 
QT (ms) 45.5 ± 3.1  49.6 ± 3.1  41.5. ± 1.5  52.5 ± 2.9a 
 
All values are shown as means ± SEM for n mice, statistically significant difference (P< 0.05) by all 
groups comparison.  
a; P< 0.05 vs XIRP1XIRP2 dko sham  
b; P< 0.05 vs XIRP WT sham 
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QRS and QT interval can be explained by an increase in conduction time in the ventricle probably 
because of cardiac hypertrophy and fibrosis.  
 
3.5.2 The ECG variations 
In this chapter examples for the different ECG variations are given. Fig. 3.22 demonstrates two 
normal mouse ECG recorded from XIRP WT sham (A) and TAC (B). 
 
Figure 3.22 ECGs from XIRP WT sham and TAC. ECGs of a XIRP WT sham (A) and XIRP 
WT TAC mouse with normal sinus rhythm are plotted. In (B) a 50 Hz disturbance is visible. 
Digitizing frequency was 1 kHz in all ECGs. 
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In Figure 3.23 a physiological ECG from a XIRP1XIRP2 dko sham heart is compared to a 
XIRP1XIRP2 dko TAC heart. The TAC heart exhibits a ventricular extra systole (arrow) followed 
by a P wave triggered by the sinus rhythm.  This P wave is unable to excite the ventricle, possibly 
due to a refractory AV-node. 
 
 
 
 
Figure 3.23 ECGs from XIRP1XIrp2 dko sham (A) and TAC (B) mice. 
(A) An ECG with normal sinus rhythm is demonstrated. (B) This ECG from a XIRP1XIRP2 dko TAC 
mouse shows an extra systole (arrow) followed by a P wave and then a pause before the normal sinus 
rhythm is restored. 
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Biphasic P waves appeared only in XIRP1XIRP2 dko mice, surprisingly to a higher amount in 
sham (38%) than in TAC animals. Two examples, one in a sham (A) and one in a TAC (B) 
animal, are demonstrated in Fig. 3.24. 
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Figure 3.24 ECGs from XIRP1XIRP2 dko sham (A) and TAC (B) mice. 
Both ECGs exhibit biphasic P waves marked by arrows in (A) and (B). 
 Results 
 
One XIRP1XIRP2 dko TAC mouse developed a ST elevation (arrow), which can be taken as an 
indication for a ischemia. Also biphasic P waves can be identified in figure 3.25. 
 
 
 
 
 
 
  
Figure 3.25 ECG from a XIRP1XIRP2 dko TAC mouse. 
The ECG of the XIRP1XIRP2 dko TAC mouse exhibits an ST elevation (arrow).  
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3.6 Comparison of three month old with one year old mice  
3.6.1 HW, HW/BW ratio, and HW/TL ratio 
To investigate whether the XIRP1XIRP2 dko mice develop a spontaneous cardiac hypertrophy 
when they become older, one year old mice of the XIRP WT and knockout genotypes were 
inspected for their heart weight parameters. The data were compared to those of three month old 
mice, which have already been presented in chapter 3.1.7. The absolute HW was significantly 
higher in the case of the older WT animals. However, the XIRP1XIRP2 dko hearts gained only 
moderately weight during aging, which was not sufficient to reach the level of significance. 
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Figure 3.26 HW, HW/BW ratio and HW/TL ratio of XIRP WT and XIRP1XIRP2 dko 3 month-old 
and 1 year-old mice. HW and HW/TL ratio of XIRP WT 1 year-old mice were significantly higher 
than all other corresponding groups (A, C). HW/BW ratio of XIRP1XIRP2 dko 1 year-old mice was 
significantly smaller than the two 3 month old groups. The data are represented as mean ± SEM; n= 3-
23 /group, *P< 0.05 was considered statistically significant. 
 
 Results 
 
Consequently, the HW was significantly higher in one year old WT mice than in the 
XIRP1XIRP2 dko mice (3 month old XIRP WT HW 127 ± 2.1 mg n= 8 and 1 year-old 168.7 ± 
9.5 mg n = 3 vs. 3 month old XIRP1XIRP2 dko HW 129.2 ± 3.8 mg n = 20 and 1 year old 141.7 
± 9.6 mg n = 6). As the animals gained relatively more BW than HW, the HW/BW ratio fell in 
both genotypes, reaching the level of significance in XIRP1XIRP2 dko mice (3 month old XIRP 
WT HW/BW ratio 5.6 ± 0.08 n= 11 and 1 year-old 5.03 ± 0.36 mg/g n = 3 vs. 3 month old 
XIRP1XIRP2 dko HW/BW ratio 5.6 ± 0.1 n = 23 and 1 year old 4.7 ± 0.2 mg/g n = 6). The 
standardization of HW to TL resulted in a comparable situation as in case of the absolute HW (3 
month old XIRP WT HW/TL ratio 8.23 ± 0.19 mg/mm n = 11 and 1 year-old 10.4 ± 0.6 mg/mm 
n=3 vs 3 month old XIRP1XIRP2 dko HW/TL ratio 7.7 ± 0.2 n = 23 and 1 year old 8.0 ± 
0.5 mg/mm n = 5) (Figure 3.26 A, B, and C). 
 
3.6.2 LVW, LVW/BW ratio, and LVW/TL ratio 
An equal comparison of LVW, LVW/BW and LVW/TL among the four groups, described in 
chapter 3.6.1 for the HW parameters, revealed comparable results. The absolute LVW was 
significantly highest in one year old XIRP WT compared to all other groups (3 month old XIRP 
WT LVW 96.5 ± 3.2 mg n = 6 and 1 year-old 126.0 ± 4.0 0.3 mg n = 3 vs. 3 month old 
XIRP1XIRP2 dko LVW 90.3 ± 4.2 n = 9 and 1 year old 98.8 ± 7.1 mg n = 5) (Figure 3.27 A). 
LVW/BW ratio was smallest in the one year old XIRP1XIRP2 dko compared to the three other 
groups, reaching significance only in comparison to the three month old groups (3 month old 
XIRP WT LVW/BW ratio 4.3 ± 0.1 n = 6 and 1 year-old 3.8 ± 0.33 mg/g n = 3 vs. 3 month old 
XIRP1XIRP2 dko LVW/BW ratio 3.9 ± 0.1 mg/g n = 9 and 1 year old 3.4 ± 0.2 mg/g n = 6). Like 
LVW, also the LVW/TL ratio was significantly highest compared to all other groups (3 month old 
XIRP WT LVW/TL ratio 6.2 ± 0.2 mg/mm n = 6 and 1 year-old 7.7 ± 0.2 mg/mm n=3 vs 3 month 
old XIRP1XIRP2 dko LVW/TL ratio 5.5 ± 0.2 n = 9 and 1 year old 6.0 ± 0.3 mg/mm n = 6) 
(Figure 3.27 A, B, and C) 
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Figure 3.27 LVW, LVW/BW ratio and LVW/TL ratio of 3 month-old and 1 year-old XIRP WT and 
XIRP1XIRP2 dko mice. LVW and LVW/TL ratio of XIRP WT 1 year-old mice were significantly 
higher than all other corresponding groups (A, C). LVW/BW ratio of XIRP1XIRP2 dko 1 year-old 
mice was significantly smaller than that of the two 3 month old groups. The data are represented as 
mean ± SEM; n= 3-23 /group, *P< 0.05 was considered statistically significant. 
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3.6.3 LW, LW/BW ratio, and LW/TL ratio  
Like described in the chapters 3.61 and 3.6.2 for HW and LVW parameters also absolute LW was 
investigated comparably. Absolute LW was highest in the one year old XIRP WT mice, reaching 
significance only vs the two three month old groups (3 month old XIRP WT LW 150.8 ± 3.0 mg 
Figure 3.28 LW, LW/BW ratio, and LW/TL ratio of 3 month-old and 1 year-old XIRP WT and 
XIRP1XIRP2 dko mice. LW was significantly higher in XIRP WT 1 year-old than both 3 month old 
groups. LW/BW ratio was significantly lower in one year old compared to three month old mice in 
both genotypes. LW/TL ratio of 1 year-old mice was slightly higher than 3 month-old mice but did 
not reach level of significance in both genotypes. The data are represented as mean ± SEM; n= 3-20 
/group, *P< 0.05 was considered statistically significant.  
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n = 11 and 1 year-old 177.7 ± 2.7 mg n = 3 vs. 3 month old XIRP1XIRP2 dko LW 144.4 ± 4.2 n 
= 23 and 1 year old 161.3 ± 7.1 mg n = 5) (Figure 3.28 A). In case of LW/BW both one year old 
groups were significantly smaller than the two 3 month old groups, but they did not differ among 
each other (3 month old XIRP WT LW/BW 6.5 ± 0.71 n = 11 and 1 year-old 5.4 ± 0.6 mg/g n = 3 
vs. 3 month old XIRP1XIRP2 dko LW/BW 6.3 ± 0.1 mg/g n = 23 and 1 year old 5.4 ± 0.1 mg/g n 
= 6). LW/TL ratio of 1 year-old mice was slightly higher than in 3 month-old mice but not reach 
level of significance within both genotypes (3 month old XIRP WT LW/TL ratio 9.5 ± 
0.2 mg/mm n = 11 and 1 year-old 10.9 ± 0.2 mg/mm n=3 vs 3 month old XIRP1XIRP2 dko 
LW/TL ratio 8.7 ± 0.2 n = 23 and 1 year old 9.5 ± 0.4 mg/mm n = 6) (Figure 3.28 A, B, and C).  
 
3.6.4 HW, HW/BW ratio and HW/TL ratio after TAC 
As a sign for a spontaneous development of cardiac hypertrophy could not be detected in the one 
year old XIRP1XIRP2 dko mice TAC was applied to these old mice. The development of cardiac 
hypertrophy was compared between the three month old and the one year old animals. The data of 
the three month old mice are the same as those presented in chapter 3.2. In the three month old 
TAC induced a significant increase of HW, HW/BW ratio and HW/TL ratio in both genotypes. 
However, even in a limited post-test (Sidak´s multiple comparison test) comparing only the four 
sham groups of interest with the respective TAC groups the one year old animals did not reach the 
level of significance. This may in part be attributed to the smaller amounts of old animals which 
were available (XIRP WT 3 month old sham n = 8 vs TAC n = 16; 1 year old sham n = 3 vs. TAC 
n = 4; XIRP1XIRP2 dko 3 month old sham n = 20 vs. TAC n = 27; 1 year old sham n = 6 vs. 
TAC n = 13). But the percentage of cardiac growth, which was achieved within 14 days was 
clearly smaller in the older animals (HW of XIRP WT 3 month old 28.9% vs 1 year old 14.4% 
growth, of XIRP1XIRP2 dko 3 month old 33.3% vs. 1 year old 25.6% growth) (Fig. 3.29 A).  
 Results 
 
In case of HW/BW, again the two genotypes of three month old mice reached a significant 
hypertrophy within 14 days. In the groups of the one year mice the XIRP1XIRP2 dko mice 
reached the level of significance in the limited post-test also applied in HW. The level of HW/BW 
gained the older animals during TAC was smaller than in the younger like in case of HW 
(HW/BW of XIRP WT 3 month old 21.1% vs 1 year old 13.4% growth, of XIRP1XIRP2 dko 3 
month old 27.8% vs. 1 year old 22.2% growth) (Fig. 3.29 B).  
Figure 3.29 HW, HW/BW and HW/TL ratio of 3 month-old and 1 year-old XIRP WT and 
XIRP1XIRP2 dko mice after 14 days TAC. HW, HW/BW ratio, and HW/TL ratio of 3 month-old 
mice were significantly increased in both genotypes. For 1 year-old mice the same parameters were 
increased but only HW/BW of XIRP1XIRP2 dko mice reached the level of significance. The data are 
represented as mean ± SEM; n= 3-27 /group, *P< 0.05 was considered statistically significant. 
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Also in the HW/TL ratio both genotypes of the three month old mice gained a significant 
hypertrophy within 14 days, whereas the one year old mice did not reach the level of significance 
within this time even in the limited post-test. The increases in HW/TL were: HW/TL of XIRP WT 
3 month old 26.6% vs 1 year old 10.4% growth, of XIRP1XIRP2 dko 3 month old 37.7% vs. 1 
year old 15.9% growth (Fig. 3.29 C). 
 
 
3.6.5 LVW, LVW/BW ratio and LVW/TL ratio after TAC 
 
Like HW also LVW was evaluated after TAC of the one year old mice. The data of the three 
month old mice are the same as those presented in chapter 3.2. In the three month old mice TAC 
induced a significant increase of LVW, LVW/BW ratio and LVW/TL ratio in both genotypes. 
However, even in a limited post-test comparing only the four sham groups of interest with the 
respective TAC groups the one year old animals XIRP WT did not reach the level of significance 
in any of the three tested parameters. In contrast, the XIRP1XIRP2 dko TAC mice developed 
significant hypertrophy in all three parameters. This may in part be attributed to the smaller 
amounts of old animals which were available (XIRP WT 3 month old sham n = 6 vs TAC n = 8; 1 
year old sham n = 3 vs. TAC n = 4; XIRP1XIRP2 dko 3 month old sham n = 9 vs. TAC n = 8; 1 
year old sham n = 5 vs. TAC n = 12). But the percentage of cardiac growth, which was achieved 
within 14 days was clearly smaller in the older animals (LVW of XIRP WT 3 month old 22.0% vs 
1 year old 12.5% growth, of XIRP1XIRP2 dko 3 month old 40.0% vs. 1 year old 26.8% growth). 
Interestingly the differences were only small in case of LVW/BW (LVW/BW of XIRP WT 3 
month old 17.3% vs 1 year old 14.2% growth, of XIRP1XIRP2 dko 3 month old 29.4% vs. 1 year 
old 27.0% growth). (LVW/TL of XIRP WT 3 month old 22.6% vs 1 year old 11.9% growth, of 
XIRP1XIRP2 dko 3 month old 41.5% vs. 1 year old 25.4% growth)  
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3.6.6 LW, LW/BW ratio, and LW/TL ratio after TAC 
As described in chapter 3.6.4 and 3.6.5 for HW and LVW also the LW of the one year old mice 
was evaluated after TAC and compared to the data of three month old mice. The data of the three 
month old mice are the same as those presented in chapter 3.2. In the three month old mice TAC 
induced a significant increase of LW and LW/TL ratio in both genotypes. In case of LW/BW ratio 
Figure 3.30 LVW, LVW/BW and LVW/TL ratio of 3 month-old and 1 year-old XIRP WT and 
XIRP1XIRP2 dko mice after 14 days TAC. All three tested parameters (A-C) were significantly 
increased in 3 month-old mice in both genotypes. In 1 year-old mice the same parameters were 
significantly increased in XIRP1XIRP2 dko mice. The data are represented as mean ± SEM; n= 3-12 
/group, *P< 0.05 was considered statistically significant. 
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only the three month old XIRP1XIRP2 dko 3 exceeded the level of significance. 
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In the one year old mice none of the three LW parameters reached the level of significance even 
in a limited post-test. Again the groups of old animals were relatively small (XIRP WT 3 month 
old sham n = 11 vs TAC n = 16; 1 year old sham n = 3 vs. TAC n = 4; XIRP1XIRP2 dko 3 month 
Figure 3.31 LW, LW/BW ratio, LW/TL ratio of 3 month-old and 1 year-old XIRP WT and 
XIRP1XIRP2 dko mice after 14 days TAC. After 14 days TAC LW (A) LW/TL ratio (C) ratio were 
significantly increased in both genotypes at 3 month of age, whereas the LW/BW ratio had grown 
only in the XIRP1XIRP dko mice at this age. In the 1 year old mice a significant influence of TAC 
was not detected in any of the parameters. The data are represented as mean ± SEM; n= 3-20 /group, 
*P< 0.05 was considered statistically significant. 
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old sham n = 23 vs. TAC n = 30; 1 year old sham n = 6 vs. TAC n = 13). But the percentage of 
lung growth, which was achieved within 14 days was not clearly smaller in the old than in the 
young mice neither in LW nor in LW/BW ratio nor in LW/TL ratio (LW of XIRP WT 3 month 
old 16% vs 1 year old 17.7% growth, of XIRP1XIRP2 dko 3 month old 15% vs. 1 year old 5% 
growth; LW/BW ratio of XIRP WT 3 month old 12% vs 1 year old 19.7% growth, of 
XIRP1XIRP2 dko 3 month old 9.3% vs. 1 year old 11.5% growth; LW/TL ratio of XIRP WT 3 
month old 18.2% vs 1 year old 17.2% growth, of XIRP1XIRP2 dko 3 month old 15.8% vs. 1 year 
old 9.8% growth).  
 
3.6.7 Hemodynamic parameters in 3 month and 1 year-old mice after 14 days of TAC 
TAC surgery significantly increased SAP and LVSP in both genotypes at both ages reaching 
comparable levels in all groups with one exception in the 1 year XIRP1XIRP2 dko group. In these 
mice SAP reached only 144 1 ± 2.3 mmHg which was significantly below the 158 ± 5.1 mmHg 
recorded in their 3 month old littermates (Fig. 3.32 A, B). EDP became elevated in all TAC mice 
but did not reach to the level of significance the one year old XIRP WT mice (Fig. 3.32 C). HR 
was significantly elevated in both three month old TAC groups but remained unchanged in the 
older mice (Fig. 3.32 D). dP/dtmax became significantly faster in three month-old TAC XIRP WT 
mice and showed a trend to increase in the equally old XIRP1XIRP2 dko mice. In the older mice 
TAC induced a decrease of dP/dtmax being significant only in the XIRP1XIRP2 dko mice (Fig. 
3.32 E). dP/dtmin became faster in all TAC groups of both genotypes and ages but reached 
significance only in the three month old groups (Fig. 3.32 F). 
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Figure 3.32 Hemodynamic data of XIRP WT and XIRP1XIRP2 dko 3 month-old and 1 year-old 
mice after 14 days TAC.  (A, B) TAC surgery increased SAP and LVSP in both genotypes and at 
both ages. (C) EDP was also increased in TAC mice groups, without reaching significance in the 1 
year old WT mice. (D) HR was significantly elevated in both 3 month old TAC groups (E, F) 
dP/dtmax became faster in the 3 month old XIRP1XIRP2 dko TAC mice. dP/dtmax became 
significantly faster in both genotypes in the young groups. The data are represented as mean ± SEM; 
n= 3-23 /group, *P< 0.05 was considered statistically significant.  
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SAP and LVSP 3 month-old: XIRP WT: sham SAP 107.5 ± 2.0 mmHg vs. TAC 160.3 ± 
4.5 mmHg; sham LVSP 106.8 ± 3.6 mmHg vs. TAC 158.8 ± 5.1 mmHg; XIRP1XIRP2 dko: sham 
SAP 104.1 ± 2.0 mmHg vs. TAC 156.8 ± 2.2 mHg; sham LVSP 99.3 ± 2.6 mmHg vs. TAC 156.6 
± 1.8 mmHg; 1 year-old: XIRP WT sham 106.0 ± 3.2 mmHg vs. TAC 150.0 ± 2.0 mmHg; sham 
110.6 ± 7.8 mmHg vs. TAC 153.8 ± 5.3 mmHg; XIRP1XIRP2 dko sham SAP 107.3 ± 4.8 mmHg 
vs. TAC 144.1 ± 2.3 mmHg; sham LVSP 104.1 ± 3.8 mmHg vs. TAC 145.7 ± 4.7 mmHg. 
EDP 3 month-old: XIRP WT: sham 8.8 ± 1.6 mmHg vs. TAC 12.1 ± 2.1 mmHg; XIRP1XIRP2 
dko: sham 6.7± 1.0 mmHg vs. TAC 13.2 ± 0.1 mmHg; 1 year-old: XIRP WT sham 5.4± 0.4 
mmHg vs. TAC 10.4 ± 1.4 mmHg; XIRP1XIRP2 dko: sham 5.7± 1.1 mmHg vs. TAC 14.8 ± 1.3 
mmHg. 
HR 3 month-old: XIRP WT: sham 509.3 ± 11.6 beat/min vs. TAC 590.3 ± 12.6 beat/min; 
XIRP1XIRP2 dko: sham 535.7± 11.8 beat/min vs. TAC 576.1 ± 6.5 beat/min; 1 year-old: XIRP 
WT sham 509.3 ± 11.6 beat/min vs. TAC 590.3 ± 12.6 beat/min; XIRP1XIRP2 dko: sham 535.7 
± 11.8 beat/min vs. TAC 576.1 ± 6.5 beat/min.  
dP/dtmax 3 month-old: XIRP WT: sham 9470.7 ± 583.8 mm Hg/s vs. TAC 11739.5 ± 610.1 mm 
Hg/s; XIRP1XIRP2 dko: sham 8570.8 ± 248.8 mm Hg/s vs. TAC 9729.2 ± 349.3 mm Hg/s; 1 
year-old: XIRP WT: sham 11850.2 ± 1799.1 mm Hg/s vs. TAC 9526.4 ± 433.63 mm Hg/s; 
XIRP1XIRP2 dko sham 11878.6 ± 1192.6 mm Hg/s vs. TAC 9340.27 ± 668.1 mm Hg/s.  
dP/dtmin 3 month-old: XIRP WT: sham -10525.1 ± 535.2 mm Hg/s vs. TAC -12255.7 ± 767.6 
mm Hg/s; XIRP1XIRP2 dko: sham -9651.5 ± 382.5 mm Hg/s vs. TAC -11044.2 ± 381.0 mm 
Hg/s; 1 year-old: XIRP WT: sham -10828.1 ± 1309.0 mm Hg/s vs. TAC -13138.0 ± 755.5 0 mm 
Hg/s; XIRP1XIRP2 dko: sham -8762.7 ± 107.9 mm Hg/s vs. TAC -10837.6 ± 616.7 mm Hg/s.  
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 4 Discussion 
The current investigation is focused on the role of Xin repeat-containing proteins (XIRPs) in the 
heart. In mice and humans the XIRP protein family has two members, XIRP1 and XIRP2. XIRP1 
has been reported to be a part of the fascia adherens of the ICD (Sinn et al., 2002) and to co-
localize with filamin C and aciulin (Molt et al., 2014). A previous study on XIRP1 deficient mice 
has revealed a mild cardiac phenotype under resting conditions (Otten et al., 2010). XIRP1 
deficient mice exhibited an elevated amount of non-terminal ICDs together with signs of a faster 
conduction velocity of the ventricular-specific conduction system and subtle changes in the 
shortening behavior of isolated cardiomyocytes. In a follow-up study (Kebir et al. in prep) the 
XIRP1 deficient mice were exposed to TAC and these mice developed an extent of cardiac 
hypertrophy comparable to that of their WT littermates. Also hemodynamic parameters measured 
14 days after TAC did not differ between both genotypes. The only parameter which differed 
clearly between the genotypes after TAC was a higher incidence for ventricular tachycardia after 
TAC in the XIRP1 deficient mice. In the current study mice deficient of XIRP1 and hypomorphic 
of XIRP2 were investigated, because a possible compensation of the XIRP1 protein deficiency by 
an up-regulation of the XIRP2 expression should be excluded.  
Without stimulation the two genotypes investigated here did not show any macroscopic cardiac 
differences at three month of age. However, the one year old XIRP1XIRP2 dko mice had 
significantly smaller HW and LVW than their WT littermates of the same age. Under the stress of 
TAC the three month old XIRP WT and XIRP1XIRP2 dko mice both developed cardiac 
hypertrophy. However, the degree of hypertrophy did not vary among the genotypes with respect 
to the macroscopic cardiac parameters at the age of three month mice. In contrast, the one year 
old XIRP1XIRP2 dko developed significant cardiac hypertrophy within two weeks whereas the 
XIRP WT mice exhibited only a tendency to cardiac hypertrophy. One difference between both 
 Discussion 
 
genotypes after TAC became obvious at microscopic level. There was a significantly lower 
degree of cardiac fibrosis in the XIRP1XIRP2 dko mice compared to XIRP WT.  
As XIRP1 and XIRP2 are part of the cytoskeleton and are mainly found in the ICDs of the heart, 
the ICDs were specifically investigated in by antibody staining of isolated cardiomyocytes. The 
following proteins were visualized by antibodies in cardiomyocytes isolated from hearts of sham 
and TAC mice of both genotypes: filamin, titin, cadherin, connexin43, myomesin and ryanodine 
receptors. Interestingly, the cardiomyocytes of the XIRP1XIRP2 dko mice exhibited less non-
terminal ICDs than those of the XIRP WT mice. Except the described differences in the 
distribution of ICDs no further differences in the cytoskeletal proteins were detected. 
Finally, the function of the hearts was investigated by arterial and intraventricular pressure 
catheter recordings and by ECG recordings. Under control conditions the XIRP1XIRP2 dko mice 
exhibited the same hemodynamic parameters as the XIRP WT mice. Furthermore, both genotypes 
reacted comparably to TAC stimulation concerning the hemodynamic performance of the hearts. 
In ECG recordings some genotype differences could be detected: Biphasic P waves appeared 
more often in XIRP1 XIRP2 dko mice than in XIRP WT. However, this did not depend on the 
TAC as they appeared most often in the sham and not in the TAC group.  Furthermore, TAC 
induced changes in the ECG parameters i.e. prolongation of P wave duration, of PQ interval, of 
QRS time and of QT interval were most pronounced and significant in XIRP1XIRP2 dko group 
and this may be taken as a sign for a slowed down conduction velocity.  
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4.1 Mouse model 
In the current study mice were used as model for research on the cardiovascular system. This 
seems to be justified as the mouse model it is noteworthy similar to human in case of anatomy, 
physiology and genetics (Oliver et al., 2007). Human and mouse are both mammals and it has 
judged that the gene function and physiology are well preserved among them. This is 
substantiated by the finding that mice and humans exhibit more than 95% genome similarity (Kim 
et al., 2010). Additionally, mice are small and have a short and accelerated lifespan (one mouse 
year equals about 30 humans years) that allows the researcher to save costs, space and time 
required to perform experiments at a manageable speed. Furthermore, the mouse is the only 
species, which allows to track the function of proteins by the techniques of gene knockout, 
knockin, and knockdown (Cutler et al., 2007; Oliver et al., 2007). 
In contrast to these advantages, some disadvantages of the mouse model have to be taken into 
account. Concerning cardiovascular research, mice have some differences compared to humans 
the HR are extremely high and thus there are differences in the recorded ECGs as well as in the 
underlying action potentials. In order to generate their extremely high HR short action potentials 
are necessary therefore mice express different K+ channels in the heart than humans (Nerbonne et 
al., 2001). Nevertheless, in case of targeted deletion of genes as performed here the mouse is still 
the only experimental mammalian animal to be used. 
4.2 Hypertrophy model (TAC) 
Cardiac hypertrophy is an independent risk factor for the development of heart failure. Thus 
different ways to induce cardiac hypertrophy in animal models have been developed. Among 
these the TAC model is one of the most widely used microsurgical models which was first 
established by Rockman et al 1991. Application of the TAC to mice has been shown to cause a 
proceeding growth of cardiac tissue, which can be demonstrated already three days after the initial 
surgery (Baumgarten et al., 2006; Ehrentraut et al., 2011; Nakamura et al 2001; Velten et al., 
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2012; Weisheit et al., 2014). This growth of cardiac mass reaches its maximum ten to 14 days 
after the surgery (Meyer et al., 2007; Nakamura et al., 2001). Four weeks after TAC the 
compensated hypertrophy starts to proceed into dilated cardiac hypertrophy, which may be 
reached after 6-8 weeks, depending on the severity of obstruction (de Almeida et al., 2010).  
To standardize the degree of aortic constriction a 27-gauge needle was used as a placeholder in 
this study. This treatment allows reducing the inner aortic diameter by 65-70% (Baumgarten et 
al., 2002). 
4.3 TAC-induced changes in macroscopic parameters  
4.3.1 Mortality 
A good measure for the quality of the surgery by which the TAC is executed is the mortality of 
the animals. Interestingly, the published mortality values varied over a wide range from < 25% up 
to >75%. Although the investigators all used the described 27-gauge needles and all applied TAC 
to male C57BL/6 mice. Mortality rates < 25% were reported by Barrick et al. (2007), Divakaran 
et al. (2009), Lucas et al. (2010), Rothermel et al. (2005), and Shimura et al. (2008) whereas 
others obtained 25%–50% (Nakamura et al., 2001; Liao et al., 2002; Skavdahl et al., 2005; 
Yamamoto et al., 2006; Xu et al., 2008). Higher mortality rates 50%–75% were found by 
Johnston et al. (2009) and Suryakumar et al. (2010). Mortality rates of greater than 75% have 
been reported by Jacobshagen et al. (2008) Raher et al. (2008) and Mohammed et al. (2011). The 
reasons for death can dependend on the expertise of the surgeon i.e. minor experience may lead to 
bleeding from damaged vessels, respiratory distress, pneumothorax, respiratory failure or HF. In 
this study, the mortality rate in the sham groups was 0% and in the XIRP WT TAC group it was 
10%. These mortality rates are very low compared to those reported above. In the XIRP1 XIRP2 
dko the mortality rate was 16.2% which is also low, however genetically modified mice may 
exhibit different survival rates than WT (Bourajjaj et al., 2008; van Oort et al., 2010).  
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4.3.2 Body weight  
In the group of the three month old mice our XIRP WT and XIRP1XIRP2 dko mice were 
significantly heavier than the age matched C57BL/6 mice bred in Bonn. But the body weight of 
these mice was compatible to the body weight information chart of Jackson laboratory, that listed 
a body weight of 20.2 ± 1.4 g to 21.7 ± 1.5 g for female C57BL/6 mice at the age of 11-13 weeks. 
In case of stress or sickness mice easily lose body weight TAC surgery is an invasive method that 
puts strain on the mice. Nevertheless, almost all of the mice had gained a small non-significant 
amount of body weight after two weeks. Interestingly there was no difference between the TAC 
and the sham groups. This can be taken as a sign that the animals had recovered nearly completely 
during the 14 days after surgery. 
 
4.3.3 Age of the mice  
According to Flurkey and Harrison (2007) mature life of mice can be divided into three age 
ranges 3-6 month-old (mature adult), 10-14 month-old (middle aged), and 18-24 month-old (old 
age). As we know, in human as well as in animals, the aging heart undergoes structural and 
functional changes that diminish its capability to respond to overload, and to reserve its ability in 
cardioprotection and repair processes (Lakatta, 2015). Furthermore, the XinAB-/- mice, which can 
express XinC still, develop fibrosis, conduction defects and signs of cardiomyopathy only at 
higher age (Gustafson-Wagner et al., 2007). Therefore, in this study two age groups were 
included the mature adult age 3 month-old (11-13 week-old) and middle aged 12-13 month-old 
(44-52 week-old). Especially, the 3 month-old mice have been investigated in various 
publications of our and other groups (Babiker et al., 2006; Baumgarten et al., 2006; Ehrentraut et 
al., 2011; Kebir et al., in prep; Meyer et al., 2007; Velten et al., 2012; Weisheit et al., 2014). Thus 
the results gained on this age group can be easily compared earlier ones.  
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4.3.4 HW, LVW, and LW 
The XIRP1XIRP2 dko mice investigated in this study did not develop cardiac hypertrophy 
spontaneously. According to the literature spontaneous cardiac hypertrophy seemed possible. In 
the case of the XIRP1 deficient mice two different approaches have been applied, one leading to 
the XinAB-/- mice which were still able to express the XinC isoform (Gustafson-Wagner et al., 
2007). These mice developed cardiac hypertrophy in the higher age spontaneously. On the other 
hand there are the XinABC-/- which were designed by our group (Otten et al., 2010), these mice 
did not show cardiac hypertrophy spontaneously nor did they develop a higher degree of cardiac 
hypertrophy in the case of pressure overload (Kebir et al., in. prep). These mice were crossed with 
XIRP2 hypomorphic mice described in McCalmon et al. (2010). The XIRP2 hypomorphic mice 
exhibited a 19% increased HW/BW ratio in the age range of 9-15 weeks (McCalmon et al., 2010). 
This was attributed to additional growth of cardiac myocytes by the authors. However, the 
XIRP1XIRP2 dko mice investigated here did not show any sign of spontaneous cardiac 
hypertrophy even at the age of one year. Even more the one year old XIRP1XIRP2 dko exhibited 
a significantly lower HW/BW and LVW/BW than their three month old littermates. These lower 
ratios can be attributed to an increased BW as neither the HW nor the LVW had gained 
significant amounts of weight after 3 months. In contrast in the XIRP WT mice HW as well as 
LVW grew significantly after three months. A clear reason for this difference cannot be given 
here. However, the XinC isoform which is suspected to cause spontaneous cardiac hypertrophy is 
expressed in the XIRP WT and in the XIRP2 hypomorphic mice but not in the XIRP1XIRP2 dko 
mice. Therefore one may speculate that the missing XinC could explain the lack growth and thus 
of spontaneous hypertrophy in these mice.  
Pressure overload induced cardiac hypertrophy has been documented in numerous studies. In this 
study, the XIRP WT developed a 25% increase in HW whereas XIRP1XIRP2 dko reached 39% 
higher HW after 14 days of aortic banding. HW/BW ratio grew by 22% in XIRP WT TAC mice 
vs. 27% in XIRP1XIRP2 dko TAC mice. In female C57BL/6 mice Weisheit et al. (2014) gained a 
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HW/BW of around 30% after 6 days and after around 40% after 21 days. Skavdahl, et al. (2005) 
detected 31% increase of HW/BW in C57BL5 TAC female mice after 14 days this comparable to 
the results presented here. However, male C57BL6 exhibited a 64% increase in HW/BW in the 
same publication. This high cardiac hypertrophy in male mice was also detected by Souders et al. 
in 2012 who documented the development of cardiac hypertrophy starting day 2 after TAC 
(25%), at day 7 (71%), at day 14 (63%) and ending at day 28 (64%). This shows that the stable 
cardiac hypertrophy is reached after 7-14 days. Taken together the cardiac hypertrophy measured 
in females as HW/BW in this study is significant but somewhat below the values of others.  
As TAC induces hypertrophy mainly in the left ventricle the measurement of the weight of this 
segment of the heart alone gives better resolution. In the present study TAC induced gain in 
LVW/HW of XIRP1 WT was significant but relatively small 16%, in XIRP1 XIRP2 dko it was 
28%. In the investigation of Kebir et al. (in prep.) the TAC induced gain in the female mice 
amounted to nearly 50% in XIRP1 WT and XIRP1 deficient. Bader et al. (2012) detected 31% 
increase in LVW/BW female mice after 2 weeks of TAC. Again the values reached here were 
smaller than those of others. Possibly the banding performed in this study was less firm than that 
applied by others. 
Aortic banding causes an increase in LV afterload which in turn leads to elevation of LV 
endsystolic volume and also of LV enddiastolic volume. This induces blood congestion in the 
lung causing lung edema and compensatory fibrosis which is accompanied by leukocyte 
infiltration and vascular remodeling (Chen et al., 2012). The easiest way to document these 
remodeling processes in the lung is to determine lung weight. TAC increased LW, LW/BW ratio, 
and LW/TL ratio this study by 17%, 12% and 18% in XIRP WT vs.; 15%, 10% and 15% in 
XIRP1XIRP2 dko. However, both TAC groups did not differ significantly. The elevations of LW 
found here were in concert with the results of Xu et al. (2006) published about 20% in LW/TL 
after 14 days of TAC. 
Advancing age is correlated with an attenuated capacity to develop cardiac hypertrophy due to a 
decrease of protein synthesis in response to acute pressure overload (Isoyama et al., 1987). In 
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addition, the older mice (>12 month-old) need more time to develop vascular adaptation after 
TAC, but they proceed faster to dilated cardiomyopathy than younger mice (3-4 month-old) (Li et 
al., 2003). Furthermore, de Boer et al. (2013) have reported that aging diminishes the 
hypertrophic response to TAC. These observations can explain why also in this study, 1 year-old 
mice of both genotypes exhibited less hypertrophy in response to TAC than their 3 month-old 
littermates. However, it is worth to mention that the one year old XIRP WT mice did not develop 
significant cardiac hypertrophy within the 14 days observation period neither in the case of the 
case HW, HW/BW, and HW/TL nor in the case of LVW, LVW/BW, and LVW/TL. The 
XIRP1XIRP2 dko mice developed more cardiac hypertrophy than the XIRP WT visible TAC 
dependent significant increases HW/BW, LVW, LVW/BW and LVW/TL. This may be taken as a 
sign for a higher sensitivity to TAC in the XIRP1XIRP2 dko mice. Possible reasons for that will 
be discussed in chapter 4.3.5 
 
4.3.5 Left ventricular, septum thickness, and cardiac fibrosis 
LaPlace’s law adopted to the heart says that left ventricular wall stress caused by an increased 
transmural pressure can be reduced by increasing wall diameter.  
K = P * r / (2 * d) 
K: wall stress 
P: intraventricular pressure 
r: radius of the ventricular chamber 
d: wall diameter. 
 
In case of an increased intraventricular pressure due to the TAC a compensatory rise in wall 
diameter is expected to maintain the normal ejection fraction of the heart (Lorell and Carabello, 
2000). Consequently, the detection of the left ventricular wall diameter is a meaningful parameter, 
which was measured in the septum as well as in the wall between the papillary muscles. 2 weeks 
after TAC there was a significant increase in left ventricular wall and septum thickness in both 
genotypes (XIRP WT by about 175% and XIRP1XIRP2 dko by about 150%). Although the 
relative increase seems to be smaller in XIRP1XIRP2 dko significant differences between the 
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genotypes could not be detected. Nevertheless, the increases in wall thickness detected here are 
consistent with those from other studies like 155% in Chen et al. (2013) and like 125% in 
Speerschneider et al. (2013). These observations are also consistent with echocardiographic 
imaging after TAC for 2 weeks, which also demonstrated significant increases of LV wall 
thickness (Gao et al., 2000; Lai et al., 2012; Liao et al., 2002; Tanaka et al., 1996; Xu et al., 2008; 
Youn et al., 1999). Interestingly, did the increases in wall thickness in this investigation fit nicely 
to those from others although the weight gains were somewhat below the values in the literature. 
Also in human patients that suffer from aortic stenosis (AS) it has been shown previously that 
pressure overload usually led to increased LV wall thickness and concentric hypertrophy 
(Faggiano et al., 1994; Kehat et al., 2010). Concentric hypertrophy has been documented as the 
most common LV geometric remodeling pattern in patients with severe symptomatic AS 
(Antonini-Canterin et al., 2003). 
The concentric hypertrophy is qualified by the increase in the width of individual cardiomyocytes 
in parallel (Kehat et al., 2010). In addition, chronic pressure overload exhibited increased collagen 
accumulation between cardiomyocytes and myocyte fascicles (Weber et al., 1988) as well as 
accumulation of ECM and fibrosis followed by cardiac stiffness and then inadequate filling leads 
to insufficiency diastole function (Kehat and Molketin, 2010).  
In this study TAC induced more cardiac fibrosis in three month old XIRP WT mice (4%) than in 
XIRP1XIRP2 dko mice (2%). This interesting difference may be in conjunction with AngII. In 
the introduction it has been mentioned that the XIRP2 gene has an AngII sensitive region in its 
promotor. In their study McCalmon et al. (2010) demonstrated that AngII and the “myocyte 
enhancer factor 2A”, MEF2A, are both able to stimulate the promotor activity of XIRP2.  
AngII and MEF2A acted synergistically i.e. applied together they stimulated more than 10x, 
applied alone they stimulate 2.5x and 3.6x. In a model of AngII induced cardiac hypertrophy the 
XIRP2 hypomorphic mice displayed attenuated cardiac hypertrophy, fibrosis, and apoptosis. As 
AngII is indirectly attributing to pressure overload induced cardiac hypertrophy (Müller et al., 
2013), the reduced cardiac fibrosis in our XIRP1XIRP2 dko mice may be explained by the 
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reduced AngII signaling in these mice, especially since AngII has been shown to be pro-fibrotic 
by interaction with TGFβ1 signaling (reviewed in Leask 2015). 
 
4.3.6 Cardiomyocyte parameters 
In a comparison of the cardiomyocyte dimensions the length of the XIRP1XIRP2 dko sham cells 
proved to be significantly longer and less wide than the XIRP WT sham cardiomyocytes. This 
seems to be in contrast to the observation that the whole hearts did not differ between the 
genotypes. But as the length and width are contrary this may level out in the tissue. Interestingly, 
the isolated cardiomyocytes of XinABC-/- were also slightly but significantly longer than their 
WT counterparts (Otten et al., 2010). 
In case of the development of concentric cardiac hypertrophy one would expect an increase in 
cellular width due to the assembly of new myofibrils in parallel (Byus et al., 2007; Kehat and 
Molkentin, 2010). After TAC cardiomyocytes became shorter and wider in both genotypes, 
however, level of significance was only reached in the XIRP1XIRP2 dko cells. These 
observations seem to be in line with development of concentric cardiac ventricular hypertrophy. 
As XIRP1 and XIRP2 are part of the cytoskeleton and are mainly found in the ICDs of the heart, 
the ICDs were investigated by antibodies directed against cadherin, connexin43 and filaminA/C 
d1-2. Non-terminal ICDs were detected in a significantly lower amount in XIRP1XIRP2 dko 
sham cells (3.44 ± 0.2) than in XIRP WT sham cells (4.7 ± 0.3). TAC seemed to increase non 
terminal ICDs further in the XIRP WT sham cells (5.1 ± 0.3) but not in the XIRP1XIRP2 dko 
sham cells (3.36 ± 0.2). At the first glimpse this result seems to be surprising, because Otten et al. 
(2010) found an elevated number of non-terminal ICDs in XinABC-/- cardiomyocytes. However, 
the number was around 8 per cell there compared to about 4 - 5 in their WT cardiomyocytes. Thus 
the amount non-terminal ICDs in the XIRP WT here seems to be comparable to that of Otten et 
al. (2010). But the non-terminal ICDs of the XIRP1XIRP2 dko sham and TAC cells are extremely 
low.  
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In an effort to detect further differences in the cytoskeleton various antibodies were applied, 
against myomesin located in the M band, against a Z-band epitope of titin, and against ryanodine 
receptor as part of the triads. The localization of these proteins was neither influenced by the 
genotype nor by the TAC treatment. This is somewhat surprising as one may expect that synthesis 
of new myofibrils should require a complete remodeling of the cytoskeleton, a process on which 
the absence of both XIRP proteins should exert influence. However, the failure of the detection 
changes may also be explained by the relatively late time point after the aortic constriction. As 
mentioned in chapter 4.3.4 the cardiac hypertrophy in mice develops mainly between day two and 
seven after TAC and between one week and four weeks after TAC the amount of cardiac 
hypertrophy is relatively stable. For the detection of dynamic changes which could help to 
unmask the role the XIRP proteins further, earlier time points after TAC should be observed.   
 
4.4 TAC-induced changes in the hemodynamic parameters  
The genetic differences between the XIRP WT and XIRP1XIRP2 dko mice did not influence of 
hemodynamic parameters recorded here in the sham mice neither in the in the month old group 
(c.f. table 3.2) nor in one year old group (chapter 3.6.7). Thus spontaneous differences in the 
cardiac function could be detected.  
Inducing hypertrophic cardiac remodeling by increasing the afterload will induce mechanical 
stress to the ICDs, which in turn may cause difference due to the absence of both XIRP proteins. 
The primary pro-hypertrophic stimulus in the TAC model is a pre-stenotic elevation of blood 
pressure. Therefore it is important classify the rise in blood pressure obtained by the aortic 
constriction.  
After 14 days of TAC SAP was significantly elevated by about 150% to around 160 mmHg in 
both young groups (XIRP WT: 160.3 mmHg (149.0%), XIRP1XIRP2 dko: 156.8 mmHg 
(150.6%)). An increase in SAP by about 150% can be taken as an indication for a successful TAC 
surgery. Comparable elevations of systolic BP have published in previous studies on female mice, 
Patten et al. (2008) (157.5%, 149.0 mmHg), Witt et al. (2008) (160.0%, TAC 160 mmHg) and Xu 
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et al. (2008) (144.0% 153.0 mmHg). Furthermore, the one year old mice which were exposed to 
TAC here also reached SAP values in the same range as the young mice (XIRP WT TAC 150.0 
mmHg increase 141%; XIRP1XIRP2 dko SAP 144 mmHg increase 135%). The blood pressure 
reactions gained in the older mice were lower than in the younger ones, which points to a reduced 
ability to compensate the increased afterload. In the old XIRP1XIRP2 dko the gained pressures 
were lower than in the old XIRP WT although only the XIRP1XIRP2 dko developed a significant 
cardiac hypertrophy. 
The TAC-induced changes in the hemodynamic parameters can also be taken as a measure for 
cardiac performance. The higher the LVEDP increases the worse is the condition of the ventricle 
and the elevated LVEDP induces a progressive congestion of blood in the lungs. The LVEDP rose 
in both genotypes and age groups (3 month-old: XIRP WT from 8.8 to 12.1 mmHg; XIRP1XIRP2 
dko from 6.7 to 13.2 mmHg; 1 year-old: XIRP WT from 5.4 to 10.4 mmHg; XIRP1XIRP2 dko 
from 5.7 to 14.8 mmHg). All these increases can be regarded as moderate with the exception of 
the one year old XIRP1XIRP2 dko in which TAC increased the EDP by 9.1 mmHg. Patten et al. 
(2008) also reported an increase in LVEDP in three month old female mice from 3.1 mm Hg to 
11.8 mm Hg, which is in the same range as our values.  
In case of a compensated hypertrophy cardiac output (CO) is also maintained by increasing the 
heart rate. Significant up-regulations of HR after two weeks TAC could be proven in both 
genotypes of the three month old mice but not in the one year old groups.  
Another sign of compensated cardiac hypertrophy is an up-regulation of dP/dtmax. After 14 days of 
TAC both genotypes groups of young exhibited significantly higher dP/dtmax values than the 
respective sham groups. Differences among the genotypes were found. The hearts of the young 
mice were able to compensate the elevated afterload significant by up-regulation of dP/dtmax 
detectable only in a limited comparison (Fig. 3.20). However, XIRP1XIRP2 dko TAC developed 
significantly dP/dtmax values than the respective WT mice. In contrast, the one year old mice were 
not able to up-regulate dP/dtmax but exhibited down-regulation of the contractility, reaching the 
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level of significance in the XIRP1XIRP2 dko mice. dP/dtmin was increased in all groups, being 
significant only in the two groups of young animals. 
Taken together, according to the cardiac performance of the two young groups seem to be in the 
stage of compensated cardiac hypertrophy. Whereas the older mice seemed to have proceeded 
further on the way to HF. However, significant genotype differences were small. 
 
4.5 TAC-induced changes in the ECG  
TAC is a standard procedure to generate pressure overload in mice, causing LV hypertrophy. The 
ECG was applied here to evaluate electrical activity within the heart. The ECG analysis revealed 
that biphasic P waves appeared more often in XIRP1 XIRP2 dko mice then in XIRP WT. 
Interestingly, XIRP1XIRP2 dko exhibited more biphasic P waves in sham than in TAC 
conditions. Left atrium enlargement causes broad biphasic P waves in ECG lead II, because a 
large atrium results in a delay of the complete depolarization from right atrium to left atrium 
(Levine, Coyne & Colvin, 2015). Furthermore, pressure overload can induce atrium enlargement 
by increased left atrium afterload (Patel et al., 2009). But as biphasic P waves were more frequent 
in sham than in TAC XIRP1XIRP2 dko mice TAC does not seem to influence this phenomenon 
here. But two other atrial parameters P wave duration and PQ time were prolonged by the TAC in 
both genotypes. However, the level of significance was only reached in the XIRP1XIRP2 dko. 
The general prolongation may be attributed increased conductance distances because of an 
increased atrium or to a slowed conduction velocity.   
ST elevation is a classical hallmark of acute myocardial infarction. In the mouse ST segment 
represents mainly the ventricular repolarization. But also left ventricular hypertrophy especially of 
the septum is a common condition that is associated with ST segment elevation. However, ST 
elevation caused by septum enlargement is not as obvious as in myocardial infarction (Coppola et 
al., 2013). In this study ST elevation found in one of the XIRP1XIRP2 dko TAC mice.  
The study by Boulaksil et al. (2010) documented after 2 weeks TAC mice showed rapid structural 
and electrical remodeling leading to QRS and QT interval prolongation. This consistent with our 
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results on QRS and QT interval, as both TAC groups displayed a trend to prolongation of these 
values. In case of QT time XIRP1XIRP2 dko TAC mice reached the level of significance. QRS 
complex prolongation indicates a delayed activation of the ventricles, due to either a slowed down 
impulse conduction or an increased conduction distance due to cardiac enlargement (Wiegerinck 
et al., 2006). In aortic constriction the mice developed fibrosis which associated with slowing 
conduction, but fibrosis was significantly higher in the XIRP WT than in the XIRP1XIRP2 dko. 
Therefore fibrosis may here not be the most important factor for the prolonged QRS complex and 
QT interval.  
Another reason may be a changed structure of the ICDs. In the XinAB-/- hearts, which 
spontaneously develop a disrupted ICD structure and cardiac hypertrophy, a prolonged QT 
interval was recorded (Gustafson-Wagner et al., 2007). Interestingly, signs of a faster conduction 
velocity of the ventricular-specific conduction system were detected in the XinABC-/- mice. This 
faster conduction velocity was attributed to the increased number of ICDs in these mice (Otten et 
al., 2010). In the XIRP1XIRP2 dko mice decreased number of lateral ICDs could be shown here, 
which can contribute to the prolonged QT interval detected here.  
XinABC-/- mice exposed to TAC had a higher incidence for the development of ventricular 
tachycardia after electrical induction (Kebir et al. in prep). This parameter was not investigated in 
the present study. However, both XIRP proteins are localized in the ICD and their absence in 
XIRP1XIRP2 dko mice may cause reorganization of the ICDs especially during the hypertrophic 
remodeling. The reorganized ICDs of XIRP1XIRP2 dko mice may lead to lowered cell-to-cell 
coupling a thus a prolonged QT interval. But this observation needs further substantiation. In 
summary, TAC induced changes in ECG parameters were most pronounced and significant in 
XIRP1XIRP2 dko group and may be taken as a sign for a slowed down conduction velocity.  
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4.6 Conclusion 
In the present study we sought to determine the role of XIRP1 and XIRP2 proteins in cardiac 
structure and function. Furthermore, cardiac hypertrophic remodeling was induced in order to 
enlighten the functions of the XIRP proteins during structural adaptation of the cardiomyocytes to 
increased load. We hypothesized that an additional knock-down of XIRP2 may help to unravel 
the functions of both XIRPs in the murine heart as an up-regulation of XIRP2 may not be able 
substitute a XIRP1 deficiency. Therefore, XinABC-/- mice (Otten et al., 2010) were crossed with 
XIRP2 hypomorphic mice (McCalmon et al., 2010) and referred as XIRP1XIRP2 dko mice. 
The XIRP1XIRP2 dko mice exhibited a mild cardiac phenotype, without developing a 
spontaneous cardiac hypertrophy. The hypothesis that XinABC-/- mice do not develop severe 
phenotype because XIRP2 is able to replace the functions of XIRP1 could not be confirmed. 
Surprisingly, the phenotype of the XIRP1XIRP2 dko mice was even less pronounced than that of 
the XIRP2 hypomorphic mice, because the XIRP1XIRP2 dko sham mice did not develop a 
spontaneous cardiac hypertrophy in contrast to the XIRP2 hypomorphic mice. A possible reason 
for that could be the missing XinC isoform in the XIRP1XIRP2 dko mice which seems to play a 
role in the development of cardiac hypertrophy and failure. However, this is not proven by the 
experiments performed here. 
Only a few genotype-dependent differences could be detected. Regarding spontaneously 
appearing differences, a reduced amount of non-terminal ICDs was seen in fluorescence 
microscopy and a high rate of biphasic P waves was recorded in the XIRP1XIRP2 dko sham 
mice. As the reduced non-terminal ICDs were detected in ventricular cells and the biphasic P 
waves originate in the atrium these two observations could not be directly correlated. During 
hypertrophic remodeling a few additional XIRP dependent changes were observed. The fibrosis 
induced by cardiac overload was less distinct in XIRP1XIRP2 dko mice than in XIRP WT. 
XIRP2 has been shown to be involved in AngII signaling as its promoter is sensitive to AngII. 
AngII is known to enhance cardiac fibrosis, thus the missing XIRP2 may help to reduce the 
development of fibrosis during hypertrophic growth. 
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Finally, some functional effects of the XIRP1XIRP2 deficiency were detected in ECG recordings: 
prolongation of P wave duration, of PQ interval and of QT interval. These may be taken signs for 
reduced conduction velocity in the XIRP1XIRP2 dko TAC mice. As the XIRP1XIRP2 dko TAC 
mice exhibit less non-terminal ICDs a reduction of cellular coupling may follow, which could 
contribute to reduce conduction velocity. However, this hypothesis needs further substantiation by 
more refined ECG recordings. 
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The proteins of intercalated discs (ICDs) are components of the cardiac cytoskeleton which forms 
the scaffold of cardiomyocytes and thus helps to maintain cell shape, provide tissue integrity, and 
to stabilize the sarcomeric proteins. Part of the cytoskeleton are the Xin repeat containing proteins 
1 and 2 (XIRP1 and XIRP2), which are located in ICDs of the mammalian heart. XIRP1 and 
XIRP2 have been detected in the adherens junctions of the ICDs and play critical roles in the 
cardiac development and the structural integrity of ICDs. XIRP1-null mice created by our group 
exhibited a mild cardiac phenotype with increasing non-terminal ICDs and an increased 
intraventricular conduction velocity. Also the application of elevated afterload to XIRP1 deficient 
mice to induce hypertrophic cardiac remodeling did not lead to a more severe phenotype. Possibly 
lack of XIRP1 protein was compensated by XIRP2 up-regulation. Therefore XIRP1 deficient 
mice were crossed with XIRP2 knockdown mice (XIRP1 XIRP2 dko). We hypothesized that an 
additional knock-down of XIRP2 may help to unravel the functions of both XIRPs in the murine 
heart in case of normal and elevated afterload. 
XIRP wild-type (XIRP WT) and XIRP1XIRP2 dko female mice of about 12 weeks or one year 
age were assigned to transverse aortic constriction , TAC, or sham surgery. Surgeries were 
performed on anesthetized (2 vol % isoflurane) mice provided i.p. with analgesia (buprenorphine 
0.065 mg/kg body weight, BW). A 27 gauge needle was used to standardize the degree of aortic 
constriction. After 14 days of TAC or sham, hemodynamic parameters were recorded by a 
pressure catheter in mild anesthesia (heart rate, HR, ~500 min-1). Furthermore, surface 
electrocardiography was performed under the same conditions.  
Different morphometric parameters were measured: body weight, BW; heart weight, HW; left 
ventricular weight, LVW; lung weight, LW; tibia length, TL. From explanted hearts single 
cardiomyocytes were prepared by retrograde Langendorff-perfusion, proteins of interest were 
localized in the isolated cardiomyocytes by antibodies and visualized by immunofluorescence 
microscopy. Representative hearts from the different groups were embedded in paraffin and 
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sections from 4 different areas were cut. In light microscopy the diameters of the septum and the 
ventricular wall were determined as well as the amount of cardiac fibrosis, visualized by 
Masson’s trichrome stain. 
14 days after TAC surgery the XIRP WT and XIRP1XIRP2 dko mice of three month age had 
developed significant cardiac hypertrophy compared to the sham animals. However, both 
genotypes did not differ with respect to the measured morphological parameters (HW, HW/BW, 
HW/TL; LVW, LVW/BW, LVW/TL; LW, LW/BW; LW/TL). Also the diameters of septum and 
ventricular wall were significantly increased by the TAC but did not exhibit genotype differences. 
But TAC induced cardiac fibrosis was significantly higher in XIRP WT than in XIRP1XIRP2 dko 
mice. Protein localization performed by fluorescence microscopy revealed that XIRP1XIRP2 dko 
mice exhibited independently of TAC significantly less non-terminal ICDs than XIRP WT mice, 
whereas the number of terminally situated ICDs was not altered. Localization of proteins in the 
M-band, the Z-discs and the triads was neither influenced by genotype nor by TAC. 
The TAC elevated the systolic arterial pressure, SAP, and the left ventricular systolic pressure, 
LVSP, significantly by ~ 150% in both genotypes. Also the left ventricular end-diastolic pressure, 
LVEDP, HR, and the measures for contractility, maximal velocity of pressure increase, dP/dtmax, 
as well as maximal velocity of pressure decrease, dP/dtmin, were all up-regulated in response to 
TAC, however to the same degree in both genotypes.  
Abnormal ECG parameters were never recorded from XIRP WT mice neither in the sham nor in 
the TAC group. In contrast, ECG recordings from XIRP1XIRP2 dko sham mice exhibited 
biphasic P waves in 38.5% of the recordings. XIRP1XIRP2 dko TAC mice showed biphasic P 
waves in 18% of the evaluations, irregular HR, missing P waves and even ST elevations were 
detected. TAC induced a prolongation of P wave duration, PQ interval and QT interval in both 
genotypes. As the amount of prolongation was higher in the XIRP1XIRP2 dko TAC mice only 
these reached the level of significance. 
To find out whether there are genotype dependent phenomena which appear only in older age also 
1 year-old mice of both genotypes underwent sham and TAC surgery. They were evaluated for 
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the macroscopic morphological parameters and for the hemodynamics. The mice did not 
spontaneously develop any genotype dependent differences during aging. The cardiac growth 
gained within 14 days after TAC surgery was clearly smaller in the older mice than in the younger 
ones. Within this time span hypertrophic cardiac growth reached the level of significance only in 
the XIRP1XIRP2 dko mice, although both groups of mice responded to the excessive afterload by 
comparably increased levels of SAP, LVSP, and LVEDP.  
Taken together, only a few genotype-dependent differences could be detected. Regarding 
spontaneously appearing differences, a reduced amount of non-terminal ICDs were seen in 
fluorescence microscopy and a high rate of biphasic P waves were recorded in the XIRP1XIRP2 
dko sham mice. As the reduced non-terminal ICDs were detected in ventricular cells and the 
biphasic P waves originate in the atrium these two observations could not be directly correlated. 
TAC dependent fibrosis was less distinct in XIRP1XIRP2 dko mice. This may possibly originate 
in a changed angiotensin II, AngII, signaling. As XIRP2 expression has been shown to be 
influenced by AngII, its absence in turn may disturb AngII signaling, which is known to enhance 
fibrosis. Prolongation of P wave duration, PQ interval, QRS complex, and QT interval may be 
taken signs for reduced conduction velocity in the XIRP1XIRP2 dko TAC mice. These mice also 
exhibit less non-terminal ICDs which could contribute to reduced conduction velocity. However, 
this hypothesis needs further substantiation by more refined ECG recordings. 
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